

**ASCO**® Genitourinary  
Cancers Symposium

## PROGRAM

PATIENT-CENTERED CARE:  
**FROM DISCOVERY  
TO DELIVERY**

**February 26–28, 2026**

Moscone West | San Francisco, CA | Online

Wi-Fi Network: GU26  
No Password Required  
[gu.asco.org](https://gu.asco.org) | #GU26

**ASCO**® AMERICAN SOCIETY OF  
CLINICAL ONCOLOGY  
KNOWLEDGE CONQUERS CANCER

**ASTRO**  
AMERICAN SOCIETY FOR RADIATION ONCOLOGY

**SUO**  
SOCIETY OF UROLOGIC ONCOLOGISTS

## Contents

Committees	6
Merit Award Recipients	7
CME, MOC, and Symposium Feedback	7
Premium Ancillary Educational Events	7
Attendee Resources	8
Program at a Glance	9
Program by Day	12
Poster Directory	19
Industry Expert Theater	59
Exhibitor Directory	60

SAVE THE DATE:

## 2027 ASCO Genitourinary Cancers Symposium

February 11-13, 2027 | Moscone West | San Francisco, CA | [gu.asco.org](https://gu.asco.org)

## Committees

### Program Committee

**Andrea B. Apolo, MD (Chair)**

National Cancer Institute

**Jose Karam, MD, FACS (Chair-Elect)**

The University of Texas MD Anderson Cancer Center

**Peter Hoskin, MD, FRCP, FRCR (Immediate Past-Chair)**

Mount Vernon Cancer Centre, University of Manchester

**Julia Close, MD, MBA, FASCO (Leadership)**

ASCO

**Leslie Ballas, MD**

Cedars-Sinai

**Pedro C. Barata, MD, MSc**

University Hospitals Seidman Cancer Center

**Katy Beckermann, MD, PhD**

Tennessee Oncology

**Peter Black, MD**

University of British Columbia

**Alberto Bossi, MD**

Gustave Roussy Cancer Centre

**Mauricio Burotto, MD**

Clínica Universidad de los Andes, Bradford Hill Clinical Research Center

**Ronald C. Chen, MD, MPH, FASTRO, FASCO**

University of Kansas Cancer Center

**Marc Dall'Era, MD**

UC Davis Health

**Tanya Dorff, MD**

City of Hope

**John L. Gore, MD, MS**

University of Washington

**Brandon Mahal, MD**

University of Miami

**Katie S. Murray, DO**

NYU Langone Health

### Special thanks to the Content Advisors from the Radiological Society of North America

**Atul B. Shinagare, MD**

Brigham and Women's Hospital

**Aradhana M. Venkatesan, MD, FACP**

The University of Texas MD Anderson Cancer Center

### News Planning Team

**Julie R. Gralow, MD, FACP, FASCO**

ASCO

**William Kevin Kelly, DO, FASCO**

Thomas Jefferson University Hospital

**Brian I. Rini, MD, FASCO**

Vanderbilt University Medical Center

**William K. Oh, MD**

Yale Cancer Center

**Julian Hong, MD, MS**

University of California San Francisco

## Conquer Cancer®, the ASCO Foundation, Merit Award Recipients

Conquer Cancer, the ASCO Foundation, Merit Awards are designed to further promote quality clinical research by young scientists. A select number of Merit Awards are given annually to recognize outstanding research in abstracts submitted for presentation at the ASCO Genitourinary Cancers Symposium.

**Masoud Bitaraf, MD**, Desai Sethi Urology Institute at the University of Miami Sylvester Comprehensive Cancer Center

**Elise Cai, MD, PhD**, University of California San Francisco

**Abigail Chu**, Saint Louis University School of Medicine

**Sara Coca Membrives, MD**, Barts Cancer Institute, Queen Mary University of London

**Sophia Coraci, BS**, Weill Cornell Medicine

**Hedeyeh Ebrahimi, MD, MPH**, Beth Israel Deaconess Medical Center

**Omar El-Taji, MBChB, MRes**, Christie Hospital

**Judith Fischer**, LMU University Hospital, LMU Munich

**Diya Garg, BS**, Huntsman Cancer Institute, University of Utah

**Struan Gray, MBBCh**, Christie Hospital

**Francesca Jackson-Spence, MBChB, BSc**, Barts Cancer Institute

**Jesus Juarez Casillas, MD**, UCLA

**Madeleine Karpinski**, University of Duisburg-Essen, German Cancer Consortium (DKTK), NCT, University Hospital Essen

**Panayiotis Kontoyiannis, MD**, The University of Texas Southwestern Medical Center

**Joy Li, MD**, Fox Chase Cancer Center

**Jan-Jaap Mellema, MD**, Netherlands Cancer Institute

**Chiara Micoli, MSc**, Karolinska Institutet

**Zuzana Orszaghova, MD**, Comenius University, National Cancer Institute

**Justine Panian, MD**, University of California San Diego

**Adeel Riaz, MD, MPhil**, Rutgers Robert Wood Johnson Medical School

**Gabriel Roman Souza, MD**, Moffitt Cancer Center, University of South Florida

**Nicholas Salgia, BSc**, Roswell Park Comprehensive Cancer Center

**Koral Shah, MD**, City of Hope Comprehensive Cancer Center

**Xiaolei Shi, MD, PhD**, University of Maryland School of Medicine

**Olesia Stativko, MD**, City Clinical Hospital Named after S.S. Yudin, Moscow City Health Department

**Sarah Stewart, MBChB, MRCP, FRCR**, The Institute of Cancer Research

**Hongwei Wang, MD**, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

**Zachary Yochum, MD, PhD**, Yale Cancer Center, Yale School of Medicine

---

## CME, MOC, and Symposium Feedback

Sessions at the ASCO Genitourinary Cancers Symposium will provide Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points for physicians.

Participants should use the ASCO Meetings app to:

- Claim CME credit for sessions
- Request ABIM, ABP, and/or ABS MOC points
- Provide feedback on sessions

Share Feedback on your Meeting Experience:



Download your Certificate of Attendance at [profile.asco.org](https://profile.asco.org).

Please visit [gu.asco.org/continuing-education](https://gu.asco.org/continuing-education) for more information about how to claim credit and request MOC points for Symposium sessions.

CME claims and MOC requests are due by June 2, 2026.

For questions or assistance, contact [customerservice@asco.org](mailto:customerservice@asco.org).

## Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I = Immediate family member; Inst = My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

---

## Premium Ancillary Educational Events

Ancillary educational events are hosted independently by other CE-accredited providers and are held adjunct to the ASCO Genitourinary Cancers Symposium. They are not official events of the 2026 Genitourinary Cancers Symposium and are not sponsored, endorsed, or accredited by ASCO, the Association for Clinical Oncology, or Conquer Cancer, the ASCO Foundation.

For an up-to-date listing of events, please scan the QR code below.



ASCO and Conquer Cancer®, the ASCO Foundation, would like to thank the following major donors of the 2026 ASCO Genitourinary Cancers Symposium: Exelixis, Inc.; Lantheus; UroGen Ltd.

## Attendee Resources

### ASCO Customer Service

ASCO Customer Service, located in the Level 1 Lobby, will be available to assist you during the following times:

- Thursday, February 26: 7:00 AM-6:45 PM
- Friday, February 27: 7:00 AM-5:45 PM
- Saturday, February 28: 6:30 AM-3:00 PM

### ASCO Meetings Mobile App

Download or update the ASCO Meetings mobile app to:

- Search sessions and presentation details
- Create a customized agenda
- Read abstracts
- Pose questions to speakers during sessions
- Respond to presenter polls
- Claim CME/MOC credit

The ASCO Meetings app is available for both Apple and Android users via the app stores.

Scan the appropriate QR code below to access your device's app store:

Apple



Android



The program is also available on [asco.org/gu-program](https://asco.org/gu-program).

Attendees must use their ASCO.org username to log in to some online resources. If you need help retrieving your username or updating your primary email address for validation, visit the ASCO Customer Service Desk in the Level 1 Lobby.

### ASCO Shop and Services

New this year: Stop by ASCO Shop and Services located on Level 3 outside the General Session room to get your meeting questions answered, browse and purchase ASCO merch, and learn more about ASCO Breakthrough, coming to Singapore in 2026.

ASCO Shop and Services will be open during the following times:

- Thursday, February 26: 7:00 AM-5:45 PM
- Friday, February 27: 7:00 AM-4:45 PM
- Saturday, February 28: 7:00 AM-3:00 PM

### Connections and Community

Expand your network by participating in programming designed to help you connect with other attendees of the largest genitourinary oncology gathering in the world. The Symposium offers a variety of networking opportunities, including luncheons, poster walks, and networking receptions. Details, including dates, locations, and faculty, can be found at [gu.asco.org](https://gu.asco.org). All networking events are in-person only and open to all attendees. Space is limited and available on a first-come, first-served basis.

### Exhibits

ASCO encourages all attendees to visit the exhibits in the West Hall on Level 1 on Thursday from 7:00 AM to 6:45 PM and Friday from 7:00 AM to 5:45 PM. The exhibits offer an opportunity to extend your learning about the most advanced therapies, products, and services in cancer care.

### Lost and Found

Always keep personal belongings with you during the Symposium. Lost an item or found an item? Please visit the ASCO Customer Service Desk in the Level 1 Lobby.

### Meeting Videos, Slides, and Posters

On-demand versions of meeting videos (recordings of the sessions) and slides (downloadable slide decks) will be available to all attendees within hours of each session's conclusion. Posters will be available to all attendees on the morning of the presentation. To view these materials, visit the ASCO Meetings mobile app or visit [asco.org/gu-program](https://asco.org/gu-program).

### Nursing Room

A private space is available for use by attendees in Room 2000 on Level 2. An electrical outlet, refrigerator, and freezer are available. A Mamava nursing pod will also be available for attendees on Level 2 by the Howard Street restroom. Use the Mamava app to unlock and use the pod or go to Customer Service in the Level 1 Lobby to receive the code.

### Policies

Important policies for this Symposium, including the Attendee Code of Conduct, are available at [gu.asco.org](https://gu.asco.org).

### Poster, Coat, and Bag Check

Complimentary poster, coat, and bag check is available in the Level 1 Lobby. Items may not be left overnight. All unclaimed items at the end of the meeting will be turned over to the convention center.

### Quiet Room

A nondenominational Quiet Room is available for attendees in Room 2006 on Level 2.

### Supplies and Device Charging

Water stations, note pads, and pens are located at the entrance to the General Session Room. Power strips for charging your devices are located throughout the room. Devices can also be charged in the West Hall on Level 1 and in Spark Spaces, located in the Level 2 and 3 lobbies.

### Wi-Fi

Using personal Wi-Fi (hot spot) devices can negatively impact the attendee Wi-Fi experience. To ensure the best experience for all attendees, please refrain from using your personal Wi-Fi device.

## Program at a Glance

Thursday, February 26

7:00 AM-6:45 PM	Exhibits Open
7:00 AM-8:05 AM	Complimentary Continental Breakfast
8:05 AM-9:45 AM	Oral Abstract Session A: Prostate Cancer
9:45 AM-10:15 AM	Break
10:15 AM-11:30 AM	Treatment Selection, Response Assessment, and Monitoring Across the Spectrum of Advanced Prostate Cancer
11:30 AM-12:45 PM	Poster Session A: Prostate Cancer <i>With complimentary boxed lunch</i>
11:30 AM-12:45 PM	Trials in Progress Poster Session A: Prostate Cancer <i>With complimentary boxed lunch</i>
11:40 AM-12:40 PM	Breakout Session: Optimizing Care for Frail and Older Patients Across the Spectrum of Genitourinary Cancers* <i>With complimentary boxed lunch</i>
11:40 AM-12:40 PM	Trainee and Early-Career Networking Luncheon* <i>With complimentary boxed lunch</i>
12:45 PM-2:00 PM	Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer
2:15 PM-3:00 PM	Keynote
3:00 PM-3:30 PM	Break
3:30 PM-4:45 PM	Multidisciplinary Tumor Board: From Imaging to Molecular Insights—Tailoring Therapy Intensity in Localized/Locally Advanced Prostate Cancer
5:00 PM-5:45 PM	Rapid Oral Abstract Session A: Prostate Cancer
5:45 PM-6:45 PM	Poster Session A (Continued) <i>With complimentary wine and cheese reception</i>
5:45 PM-6:45 PM	Trials in Progress Poster Session A (Continued) <i>With complimentary wine and cheese reception</i>
6:00 PM-6:45 PM	Poster Walks: Prostate Cancer*
6:00 PM-6:45 PM	Women's Networking Reception (Open to All)*

\*Space is limited and is available on a first-come, first-served basis.

## Program at a Glance

Friday, February 27

7:00 AM-5:45 PM	Exhibits Open
7:00 AM-8:10 AM	Complimentary Continental Breakfast
8:10 AM-9:45 AM	Oral Abstract Session B: Urothelial Carcinoma
9:45 AM-10:15 AM	Break
10:15 AM-11:30 AM	Non-Muscle-Invasive Bladder Cancer Management in Transition: Integrating Emerging Evidence Into Practice
11:30 AM-12:45 PM	Poster Session B: Prostate Cancer and Urothelial Carcinoma <i>With complimentary boxed lunch</i>
11:30 AM-12:45 PM	Trials in Progress Poster Session B: Urothelial Carcinoma <i>With complimentary boxed lunch</i>
11:40 AM-12:35 PM	Breakout Session: Multidisciplinary Care of Patients With Penile Cancer* <i>With complimentary boxed lunch</i>
11:40 AM-12:35 PM	Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon* <i>With complimentary boxed lunch</i>
12:45 PM-2:00 PM	Bladder Cancer in Women: Bridging Gaps in Science and Solutions
2:00 PM-2:30 PM	Break
2:30 PM-3:45 PM	Multidisciplinary Tumor Board: Innovative Approaches to Bladder Preservation
4:00 PM-4:45 PM	Rapid Oral Abstract Session B: Urothelial Carcinoma
4:45 PM-5:45 PM	Poster Session B (Continued) <i>With complimentary wine and cheese reception</i>
4:45 PM-5:45 PM	Trials in Progress Poster Session B (Continued) <i>With complimentary wine and cheese reception</i>
5:00 PM-5:45 PM	Poster Walks: Urothelial Carcinoma*

\*Space is limited and is available on a first-come, first-served basis.

## Program at a Glance

Saturday, February 28

7:00 AM-12:45 PM	Food Room Open
7:00 AM-8:10 AM	Complimentary Continental Breakfast
7:00 AM-8:10 AM	Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers
7:00 AM-8:10 AM	Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers
8:10 AM-9:45 AM	Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer
9:45 AM-10:15 AM	Break
10:15 AM-11:30 AM	Innovations in Kidney Cancer in 2026: Diagnostics, Novel Targets, and Trial Design
11:30 AM-12:45 PM	Poster Session C (Continued) <i>With complimentary boxed lunch</i>
11:30 AM-12:45 PM	Trials in Progress Poster Session C (Continued) <i>With complimentary boxed lunch</i>
11:40 AM-12:35 PM	Women in Genitourinary Cancers Networking Luncheon (Open to All)* <i>With complimentary boxed lunch</i>
11:45 AM-12:30 PM	Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers*
12:45 PM-1:30 PM	Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer
1:45 PM-3:00 PM	Multidisciplinary Tumor Board: Challenges and Opportunities in Treating Patients With Advanced Kidney Cancer

\*Space is limited and is available on a first-come, first-served basis.

## Thursday, February 26, 2026

7:00 AM-6:45 PM

### Exhibits Open

Level 1, West Hall

7:00 AM-8:05 AM

### Complimentary Continental Breakfast

Level 1, West Hall

8:05 AM-9:45 AM

### Oral Abstract Session A: Prostate Cancer

Level 3, Ballroom

Regina Barragan-Carrillo, MD—Chair  
Instituto Nacional de Cancerologia

Alberto Bossi, MD—Chair  
Gustave Roussy Cancer Centre

### Welcome of the Day

Andrea B. Apolo, MD, FASCO  
National Cancer Institute, National Institutes of Health

### Abstract 15: Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.

First Author: Enrique Gallardo, MD

### Abstract 16: Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).

First Author: Maha H. A. Hussain, MD, FACP, FASCO

### Discussion: Evan Y. Yu, MD

Fred Hutch Cancer Center

### Abstract 305: Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis.

First Author: Amar Upadhyaya Kishan, MD

### Abstract 306: Fifteen-year survival analysis from the ASCENDE-RT randomized trial of external beam boost versus brachytherapy boost in localized prostate cancer.

First Author: Scott Tyldesley, MD, FRCPC

### Discussion: Bridget Koontz, MD

AdventHealth Orlando

### Panel Question and Answer

9:45 AM-10:15 AM

### Break

10:15 AM-11:30 AM

### Treatment Selection, Response Assessment, and Monitoring Across the Spectrum of Advanced Prostate Cancer

Level 3, Ballroom

Tanya B. Dorff, MD—Chair  
City of Hope

Michael Ong, MD, FRCPC—Chair  
The Ottawa Hospital Cancer Centre

### Making Sense of Many Options: Metastatic Hormone-Sensitive Prostate Cancer Treatment Selection

Christopher Sweeney, MBBS

South Australian Immunogenomics Cancer Institute, University of Adelaide

### Evaluation and Definition of Response and Progression From Trials to Clinical Practice

Andrew J. Armstrong, MD, MS

Duke University

### New Treatment Options for Patients With Castrate-Resistant Prostate Cancer

Dana Rathkopf, MD

Memorial Sloan Kettering Cancer Center

### Abstract 14: Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPitello-281.

First Author: Daniel J. George, MD, FASCO

### Panel Question and Answer

11:30 AM-12:45 PM

### Poster Session A: Prostate Cancer

Level 1, West Hall

*With complimentary boxed lunch. See p. 19 for a full listing of posters.*

11:30 AM-12:45 PM

### Trials in Progress Poster Session A: Prostate Cancer

Level 1, West Hall

*With complimentary boxed lunch. See p. 32 for a full listing of posters.*

11:40 AM-12:40 PM

### Breakout Session: Optimizing Care for Frail and Older Patients Across the Spectrum of Genitourinary Cancers

Level 2, Room 2007

*With complimentary boxed lunch.*

Tullika Garg, MD, MPH—Chair

Geisinger Health Systems

Jason A. Efstathiou, MD, FACRO, FASTRO—Chair

Massachusetts General Hospital

### Understanding and Overcoming Frailty in the Care of Patients With Genitourinary Cancers

Sarah P. Psutka, MD, MS

Fred Hutch Cancer Center

### Oncologic Care in Older Patients With Genitourinary Cancers

Sindhuja G. Kadambi, MD, MA, MS

University of Rochester's Wilmot Cancer Institute

### Pharmacist

Lisa M. Cordes, PharmD

National Cancer Institute, National Institutes of Health

### Physical Medicine and Rehabilitation Physician

Hanna Hunter, MD

Fred Hutch Cancer Center

### Panel Discussion With Audience Question and Answer

11:40 AM-12:40 PM

**Trainee and Early-Career Networking Luncheon**

Level 2, Room 2011

*With complimentary boxed lunch.*

12:45 PM-2:00 PM

**Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer**

Level 3, Ballroom

Stacy Loeb, MD, PhD, MS—Chair  
NYU Langone Health

Pedro C. Barata, MD, MSc, FACP—Chair  
University Hospitals Seidman Cancer Center

**What Do Patients With Prostate Cancer Really Care About?**

Erik Briers, PhD, MS  
Europa Uomo

**Minimizing Harm: Surgical Approaches to Preserve Continence and Sexual Function**

Daniel Barocas, MD, MPH, FACS  
Vanderbilt University Medical Center

**Precision Matters: How Radiation Choices Shape Quality of Life**

Ronald C. Chen, MD, MPH, FASCO  
University of Kansas Medical Center

**The Hidden Burden for Patients: Depression, Anxiety, and Decision Regret in Prostate Cancer Care**

Gabriela Ilie, PhD  
Dalhousie University

**Panel Question and Answer**

2:15 PM-3:00 PM

**Keynote**

Level 3, Ballroom

**Introduction of Keynote Speaker**

Andrea B. Apolo, MD, FASCO—Chair  
National Cancer Institute, National Institutes of Health

**Reimagining Cancer Research and Care in the Age of Artificial Intelligence**

Eliezer Mendel Van Allen, MD  
Dana-Farber Cancer Institute

**Question and Answer**

3:00 PM-3:30 PM

**Break**

3:30 PM-4:45 PM

**Multidisciplinary Tumor Board: From Imaging to Molecular Insights—Tailoring Therapy Intensity in Localized/Locally Advanced Prostate Cancer**

Level 3, Ballroom

**Urologist**

Marc Dall'Era, MD—Chair  
UC Davis Comprehensive Cancer Center

**Radiation Oncologist**

Yun Rose Li, MD, PhD—Chair  
City of Hope

**Radiologist**

Raphaële Renard Penna, MD, PhD  
Sorbonne University, APHP France

**Medical Oncologist**

Shahneen Sandhu, MBBS, FRACP  
Peter MacCallum Cancer Centre, University of Melbourne

**Genomics Physician-Scientist**

Shuang Zhao, MD  
University of Wisconsin Carbone Cancer Center

**Panel Discussion With Audience Question and Answer**

5:00 PM-5:45 PM

**Rapid Oral Abstract Session A: Prostate Cancer**

Level 3, Ballroom

Melissa Lauren Abel, MD—Chair  
National Institutes of Health

Alexandra Sokolova, MD—Chair

Oregon Health & Science University, Knight Cancer Institute

**Abstract LBA307: Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.**

First Author: Karim Fizazi, MD, PhD

**Abstract 308: External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial.**

First Author: Sarah Stewart, MBChB, MRCP, FRCR

**Abstract 309: Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARPI) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS).**

First Author: Martin Gleave, MD, FACS

**Abstract 17: Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).**

First Author: Johann S. De Bono, MD, PhD, MB, MSc

**Abstract 18: Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu] Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.**

First Author: Michael J. Morris, MD, FASCO

**Abstract 19: First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study.**

First Author: Fred Saad, MD, FRCS

**Panel Question and Answer**

5:45 PM-6:45 PM

**Poster Session A (Continued)**

Level 1, West Hall

*With complimentary wine and cheese reception. See p. 19 for a full listing of posters.*

5:45 PM-6:45 PM

**Trials in Progress Poster Session A (Continued)**

Level 1, West Hall

*With complimentary wine and cheese reception. See p. 32 for a full listing of posters.*

6:00 PM-6:45 PM

**Poster Walks: Prostate Cancer**

Level 1, West Hall

Alberto Bossi, MD—Poster Walk Leader

Gustave Roussy Cancer Centre

Alexandra Sokolova, MD—Poster Walk Leader

Oregon Health & Science University, Knight Cancer Institute

6:00 PM-6:45 PM

**Women's Networking Reception (Open to All)**

Level 1, West Hall

*Meet at the lounge area in the front of the room to participate.*

## Friday, February 27, 2026

7:00 AM-5:45 PM

### Exhibits Open

Level 1, West Hall

7:00 AM-8:10 AM

### Complimentary Continental Breakfast

Level 1, West Hall

8:10 AM-9:45 AM

### Oral Abstract Session B: Urothelial Carcinoma

Level 3, Ballroom

Katie S. Murray, DO, MS, FACS—Chair  
NYU Langone Health

David H. Aggen, MD, PhD—Chair  
Memorial Sloan Kettering Cancer Center

### Welcome of the Day

Jose A. Karam, MD  
The University of Texas MD Anderson Cancer Center

**Abstract LBA630: Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.**

First Author: Matthew D. Galsky, MD, FASCO

**Abstract LBA631: RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.**

First Author: Thomas Powles, MD, PhD, FCRP

**Discussion:** Tyler F. Stewart, MD  
University of California San Diego

**Abstract LBA632: Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.**

First Author: Pooja Ghatalia, MD

**Abstract 633: Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.**

First Author: Thomas Powles, MD, PhD, FCRP

**Discussion:** Jonathan L. Wright, MD, MS, FACS  
University of Washington

### Panel Question and Answer

9:45 AM-10:15 AM

### Break

10:15 AM-11:30 AM

### Non-Muscle-Invasive Bladder Cancer Management in Transition: Integrating Emerging Evidence Into Practice

Level 3, Ballroom

Piyush Agarwal, MD—Chair  
University of Chicago Medical Center

Fabio L. Cury, MD—Chair  
McGill University

### Optimizing Surgical Management of Non-Muscle-Invasive Bladder Cancer

Jeremy Y.C. Teoh, MD, MBBS  
Chinese University of Hong Kong

### Optimizing Radiation Therapy for Non-Muscle-Invasive Bladder Cancer

Ananya Choudhury, PhD, MA, MRCP, FRCR  
The University of Manchester

### For: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer

Noah M. Hahn, MD  
The Johns Hopkins University School of Medicine

### Against: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer

Félix Guerrero-Ramos, MD, PhD  
Hospital Universitario 12 de Octubre

**Abstract LBA629: SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).**

First Author: Robert S. Svatek, MD

### Panel Question and Answer

11:30 AM-12:45 PM

### Poster Session B: Prostate Cancer and Urothelial Carcinoma

Level 1, West Hall

*With complimentary boxed lunch. See p. 35 for a full listing of posters.*

11:30 AM-12:45 PM

### Trials in Progress Poster Session B: Urothelial Carcinoma

Level 1, West Hall

*With complimentary boxed lunch. See p. 47 for a full listing of posters.*

11:40 AM-12:35 PM

### Breakout Session: Multidisciplinary Care of Patients With Penile Cancer

Level 2, Room 2007

*With complimentary boxed lunch.*

Curtis Alvin Pettaway, MD—Chair  
The University of Texas MD Anderson Cancer Center

Philippe E. Spiess, MD—Chair  
Moffitt Cancer Center

### Surgical Strategies for Penile Preservation

Adam S. Feldman, MD, MPH  
Massachusetts General Hospital

### Lymph Node Dissection for Penile Cancer: When, How, and How Much?

Kyle M. Rose, MD, MS  
Mayo Clinic Arizona

### Medical Management of Advanced Penile Cancer

Lance C. Pagliaro, MD  
Mayo Clinic Rochester

### Panel Question and Answer

11:40 AM-12:35 PM

### Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon

Level 2, Room 2011

*With complimentary boxed lunch.*

12:45 PM-2:00 PM

**Bladder Cancer in Women: Bridging Gaps in Science and Solutions**

Level 3, Ballroom

Kelly Bree, MD—Chair

The University of Texas MD Anderson Cancer Center

Alexandra Drakaki, MD, PhD—Chair

David Geffen School of Medicine at UCLA

**Unequal Burden: Sex Differences in Bladder Cancer Presentation and Prognosis**

Matthew Mossanen, MD, MPH

Dana-Farber Cancer Institute, Brigham and Women's Hospital

**Biological Differences Underlying Sex and Gender Disparities in Bladder Cancer**

Molly Ingersoll, PhD

Institut Pasteur, Institut Cochin

**Sexual Dysfunction in Women After Local Radiation Therapy for Bladder Cancer**

Xinglei Shen, MD

University of Kansas Medical Center

**Sexual Dysfunction in Women After Local Surgical Therapy for Bladder Cancer**

Armine Smith, MD

The Johns Hopkins University School of Medicine

**Panel Question and Answer**

2:00 PM-2:30 PM

**Break**

2:30 PM-3:45 PM

**Multidisciplinary Tumor Board: Innovative Approaches to Bladder Preservation**

Level 3, Ballroom

**Abstract LBA637: Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder: The phase 2 Indi-Blade trial.**

First Author: Jan-Jaap Jelmer Mellema, MD

**Radiation Oncologist**

Leslie K. Ballas, MD—Chair

Cedars-Sinai Medical Center

**Medical Oncologist**

Pooja Ghatalia, MD—Chair

Fox Chase Cancer Center

**Medical Oncologist**

Andrea Necchi, MD

Vita-Salute San Raffaele University

**Urologic Oncologist**

Marie-Pier St-Laurent, MD

University of British Columbia

**Radiologist**

Aradhana M. Venkatesan, MD, FACP

The University of Texas MD Anderson Cancer Center

**Panel Discussion With Audience Question and Answer**

4:00 PM-4:45 PM

**Rapid Oral Abstract Session B: Urothelial Carcinoma**

Level 3, Ballroom

Mary E. Westerman, MD, FACS—Chair

The University of North Carolina

**Abstract 634: KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).**

First Author: Michiel S. Van Der Heijden, MD, PhD

**Abstract 635: Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.**

First Author: Andrea Necchi, MD

**Abstract 636: Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.**

First Author: Michiel S. Van Der Heijden, MD, PhD

**Abstract 638: Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.**

First Author: Anders Ullén, MD, PhD

**Abstract LBA639: Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC).**

First Author: Matthew D. Galsky, MD, FASCO

**Abstract 737: Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).**

First Author: Jonathan F. Anker, MD, PhD

**Panel Question and Answer**

4:45 PM-5:45 PM

**Poster Session B (Continued)**

Level 1, West Hall

*With complimentary wine and cheese reception. See p. 35 for a full listing of posters.*

4:45 PM-5:45 PM

**Trials in Progress Poster Session B (Continued)**

Level 1, West Hall

*With complimentary wine and cheese reception. See p. 47 for a full listing of posters.*

5:00 PM-5:45 PM

**Poster Walks: Urothelial Carcinoma**

Level 1, West Hall

Katie S. Murray, DO, MS, FACS—Poster Walk Leader

NYU Langone Health

David H. Aggen, MD, PhD—Poster Walk Leader

Memorial Sloan Kettering Cancer Center

## Saturday, February 28, 2026

7:00 AM-12:45 PM

### Food Room Open

Level 1, West Hall

7:00 AM-8:10 AM

### Complimentary Continental Breakfast

Level 1, West Hall

7:00 AM-8:10 AM

### Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers

Level 1, West Hall

*See p. 49 for a full listing of posters.*

7:00 AM-8:10 AM

### Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers

Level 1, West Hall

*See p. 57 for a full listing of posters.*

8:10 AM-9:45 AM

### Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer

Level 3, Ballroom

Gabriela Liliana Bravo Montenegro, MD—Chair  
National Cancer Institute

Catherine Fahey, MD, PhD—Chair  
The University of North Carolina at Chapel Hill

### Welcome of the Day

Peter Hoskin, MD, FRCP, FRCR  
Mount Vernon Cancer Centre, University of Manchester

### Abstract 417: Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

First Author: Robert J. Motzer, MD

### Abstract LBA418: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.

First Author: Toni K. Choueiri, MD, FASCO

### Abstract 420: Patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.

First Author: Sophie Merrick, MRCP, MBBS

**Discussion:** Katy Beckermann, MD, PhD  
Tennessee Oncology

### Abstract 586: Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.

First Author: Ben Tran, MBBS, FRACP

**Discussion:** Samuel A. Funt, MD  
Memorial Sloan Kettering Cancer Center

### Panel Question and Answer

9:45 AM-10:15 AM

### Break

10:15 AM-11:30 AM

### Innovations in Kidney Cancer in 2026: Diagnostics, Novel Targets, and Trial Design

Level 3, Ballroom

E. Jason Abel, MD—Chair  
University of Wisconsin School of Medicine and Public Health

Minas P. Economides, MD—Chair  
New York University

### Imaging for Renal Cell Carcinoma: Current State of the Art

Shuchi Gulati, MD, FACP, MS  
UC Davis Comprehensive Cancer Center

### Emerging Tools in Imaging in Renal Cell Carcinoma

Michael S. Hofman, MBBS, FRACP  
Peter MacCallum Cancer Centre

### Novel Targets in Kidney Cancer

Hans J. Hammers, MD, PhD  
UT Southwestern Medical Center

### Clinical Trial Designs: Thinking Outside the Box

Pavlos Msaouel, MD, PhD  
The University of Texas MD Anderson Cancer Center

### Abstract 416: CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.

First Author: Aly-Khan A. Lalani, MD, FRCPC

### Panel Question and Answer

11:30 AM-12:45 PM

### Poster Session C (Continued)

Level 1, West Hall

*With complimentary boxed lunch. See p. 49 for a full listing of posters.*

11:30 AM-12:45 PM

### Trials in Progress Poster Session C (Continued)

Level 1, West Hall

*With complimentary boxed lunch. See p. 57 for a full listing of posters.*

11:40 AM-12:35 PM

### Women in Genitourinary Cancers Networking Luncheon (Open to All)

*With complimentary boxed lunch.*

11:45 AM-12:30 PM

### Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers

Level 1, West Hall

Ray Manneh-Kopp, MD—Poster Walk Leader  
Sociedad de Oncología y Hematología del Cesar

Rana R. McKay, MD, FASCO—Poster Walk Leader  
University of California San Diego

12:45 PM-1:30 PM

### Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer

Level 3, Ballroom

Ray Manneh-Kopp, MD—Chair  
Sociedad de Oncología y Hematología del Cesar

**Abstract 421: Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma: Preliminary results from the MONSTAR-SCREEN-3 study.**

First Author: Taigo Kato, MD, PhD

**Abstract 422: Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.**

First Author: Jiwei Huang, MD

**Abstract 587: A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT).**

First Author: Jennifer King, MD

**Abstract 423: Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.**

First Author: David F. McDermott, MD

**Abstract 424: Outcome of intermittent or continuous axitinib (axi) in combination with avelumab (ave) for metastatic renal cell carcinoma (mRCC): Insights from the Tide-A and Javelin Renal 101 (JR101) trials.**

First Author: Roberto Iacovelli, MD, PhD

**ABSTRACT 537: Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.**

First Author: Chad Tang, MD, MS

**Panel Question and Answer**

1:45 PM-3:00 PM

**Multidisciplinary Tumor Board: Challenges and Opportunities in Treating Patients With Advanced Kidney Cancer**

Level 3, Ballroom

**Urologic Oncologist**

John L. Gore, MD, MS—Chair  
University of Washington Medical Center

**Medical Oncologist**

Nora Sobrevilla-Moreno, MD—Chair  
Genitourinary Tumors Clinic, Instituto Nacional de Cancerología

**Interventional Radiologist**

Andrew Gunn, MD, FSIR  
University of Kentucky

**Urologic Oncologist**

Eric A. Singer, MD, MA, MS, FACS  
The Ohio State University Comprehensive Cancer Center

**Radiation Oncologist**

Chad Tang, MD, MS  
The University of Texas MD Anderson Cancer Center

**Panel Discussion With Audience Question and Answer**

# Poster Session Directory

Thursday, February 26

11:30 AM-12:45 PM and 5:45 PM-6:45 PM

## Poster Session A: Prostate Cancer Level 1, West Hall

### Posters by Topic

#### Prostate Cancer - Advanced

- Diagnostics and Imaging: A1-A18
- Real-World Evidence: A19-A26, B1-B26, C1-C26, D1-D10
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: D11-D26, E1, E2
- Therapeutics: E3-E26, F1-F20, G1-G19, H1
- Translational Research, Tumor Biology, Biomarkers, and Pathology: G16-G20, H2-H26, J1-J26, K1

#### Prostate Cancer - Localized

- Diagnostics and Imaging: K2-K16
- Real-World Evidence: K17-K26, L1-L8
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: L9-L15
- Therapeutics: L16-L26, M1
- Translational Research, Tumor Biology, Biomarkers, and Pathology: M2-M26, N1-N4

#### Board A1 **Abstract 20: New prostate cancer risk groups by PSMA-PET (PPP3).**

First Author: Madeleine Josefine Karpinski

#### Board A2 **Abstract 21: PSMA PET versus conventional imaging in metastatic prostate cancer: Evaluation of disease volume classification in a veteran cohort.**

First Author: Harris Allen, BA

#### Board A3 **Abstract 22: Treatment interruption guided by on-treatment prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic hormone-sensitive prostate cancer (mHSPC).**

First Author: Jasmine Lee

#### Board A4 **Abstract 23: Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.**

First Author: Ravi Amrit Madan, MD

#### Board A5 **Abstract 24: Radiographic recurrence patterns for prostate cancer with pathologic lymph node involvement following PSMA-PET and radical prostatectomy.**

First Author: Sean A. Fletcher, MD

#### Board A6 **Abstract 25: Sequential flutofolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy.**

First Author: Rajesh Sehgal, MD

#### Board A7 **Abstract 26: Evaluation of ancillary multiparametric MRI features in PI-RADS 3 prostate lesions and their association with prostate cancer.**

First Author: Laura Olarte

#### Board A8 **Abstract 27: Prevalence of treatment-acquired homozygous losses (homozygous deletions) of *PTEN* from androgen receptor pathway inhibitors (ARPI) in metastatic prostate cancer.**

First Author: Marijo Bilusic, MD, PhD

#### Board A9 **Abstract 28: TP53 mutations (TP53mut) as a predictive biomarker for lutetium-177-PSMA (Lu-PSMA) vs. docetaxel benefit in post-androgen receptor pathway inhibitors (ARPI) metastatic castration-resistant prostate cancer (mCRPC).**

First Author: Harshraj Leuva, MBBS

#### Board A10 **Abstract 29: Predicting cancer organ tropism in mCRPC patients using triple-tracer PET imaging radiomics clustering from the 3TMPO cohort study.**

First Author: Brecht W. Chys, MD

#### Board A11 **Abstract 30: Diagnostic performance of <sup>18</sup>F-flutofolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: Descriptive post-hoc analysis from the phase 3 SPOTLIGHT study.**

First Author: Ashesh B. Jani, MD

#### Board A12 **Abstract 31: Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with <sup>18</sup>F-flutofolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.**

First Author: Ashesh B. Jani, MD

#### Board A13 **Abstract 32: An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flutofolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy.**

First Author: Brian T. Helfand, MD

#### Board A14 **Abstract 33: Association of prostate specific antigen (PSA) doubling time (DT) and prostate specific membrane antigen (PSMA) findings in biochemically recurrent prostate cancer (BCR).**

First Author: Melissa Lauren Abel, MD

#### Board A15 **Abstract 34: Association of radiomic skeletal muscle features on prostate T1-weighted MRI with major adverse cardiac events in prostate cancer patients.**

First Author: Harikrishnan Hyma Kunhiraman, MD

#### Board A16 **Abstract 35: Survival outcomes with lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.**

First Author: Quynh Chi Le, MD

#### Board A17 **Abstract 36: Artificial intelligence-based detection of treatment-emergent metastatic neuroendocrine carcinoma of prostate.**

First Author: Chien-Kuang Cornelia Ding, MD, PhD

#### Board A18 **Abstract 37: Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.**

First Author: Ravi Amrit Madan, MD

- Board A19** **Abstract 60: Comparative risk of medication-related osteonecrosis of the jaw and survival outcomes with RANKL inhibitors versus bisphosphonates in metastatic prostate cancer.**  
First Author: Farzeen Fatma Syed, MD, MBBS
- Board A20** **Abstract 61: A novel method of analysis that uses standard of care PSA values to help guide optimal treatment decisions in the management of metastatic prostate cancer.**  
First Author: Hui X. Huang, MD
- Board A21** **Abstract 62: Risk factors and treatment outcomes in metastatic prostate cancer with brain metastases.**  
First Author: Vincent Eric Xu, BS
- Board A22** **Abstract 63: Real-world outcomes of radium-223 in the FRONTIER study: Impact of prior up-front therapy in mCRPC.**  
First Author: Takuma Kato, MD
- Board A23** **Abstract 64: Mortality risk with androgen receptor pathway inhibitors: Real-world evidence.**  
First Author: E. David Crawford
- Board A24** **Abstract 65: Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer.**  
First Author: Olesia Stativko
- Board A25** **Abstract 66: Outcomes of radium-223 therapy in combination with enzalutamide for metastatic castration-resistant prostate cancer: A multicenter retrospective analysis in Japan.**  
First Author: Takuma Kato, MD
- Board A26** **Abstract 67: Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + darolutamide + docetaxel) for mHSPC: UK real world data from the RECOMMEND study.**  
First Author: Amit Bahl, MD, FRCP, FRCR
- Board B1** **Abstract 68: Real-world utilization and timing of initiation of bone-targeting agents (BTAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223: Results from Princess Margaret Cancer Centre (PM).**  
First Author: Ealia Khosh Kish
- Board B2** **Abstract 69: Treatment patterns and survival outcomes among lutetium 177-experienced patients with metastatic castration-resistant prostate cancer.**  
First Author: Ben Tran, MBBS, FRACP
- Board B3** **Abstract 70: Real-world comparative effectiveness of novel doublet therapies for metastatic hormone-sensitive prostate cancer.**  
First Author: Ifechukwu Benedict Nwogu, BPharm, MPH
- Board B4** **Abstract 71: National trends and predictors of inpatient palliative care utilization in metastatic prostate cancer.**  
First Author: Christopher C. Chen, DO
- Board B5** **Abstract 72: High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer.**  
First Author: Fatih Kemik, MD
- Board B6** **Abstract 73: Association of early achievement of ultra-low PSA levels with radiologic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Deniz Tural, MD
- Board B7** **Abstract 74: Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study.**  
First Author: Saby George, MD, FACP
- Board B8** **Abstract 75: Treatment utilization among patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in real-world US settings: A prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Daniel J. George, MD, FASCO
- Board B9** **Abstract 76: Trends in PSA and metastatic prostate cancer at presentation in the United States from 2004-2022.**  
First Author: Jilcha Diribi Feyisa, MD, MPH
- Board B10** **Abstract 77: Clinical outcomes among patients with metastatic hormone-sensitive prostate cancer in contemporary real-world US clinical practice: A prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Alton Oliver Sartor, MD
- Board B11** **Abstract 78: [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617) in combination with an androgen receptor pathway inhibitor (ARPI) versus <sup>177</sup>Lu-PSMA-617 alone for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Elisabeth I. Heath, MD, FACP
- Board B12** **Abstract 79: Real-world effectiveness of systemic therapies after [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Xiao X. Wei, MD
- Board B13** **Abstract 80: Efficacy of <sup>177</sup>Lu-PSMA-617 in neuroendocrine prostate cancer.**  
First Author: Peter D. Zang, MD
- Board B14** **Abstract 81: Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617) in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Daniel J. George, MD, FASCO
- Board B15** **Abstract 82: Androgen-receptor pathway inhibitors triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer.**  
First Author: Alicia K. Morgans, MD, MPH, FASCO

- Board B16** **Abstract 83: Association of *MUTYH* mutations with clinical outcomes in metastatic prostate cancer.**  
First Author: Erin Kaufman
- Board B17** **Abstract 84: Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Candace Haghighi, MD, MPH
- Board B18** **Abstract 85: Long-term outcomes with radium-223 in metastatic castration resistant prostate cancer: US patient subset of the 10-year REASSURE global study.**  
First Author: Celestia S. Higano, MD, FACP
- Board B19** **Abstract 86: Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Zdravko Vassilev
- Board B20** **Abstract 87: Clinical and biomarker characteristics of treatment-emergent neuroendocrine prostate cancer.**  
First Author: Michael Haffner
- Board B21** **Abstract 88: Outcomes of [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.**  
First Author: Neal D. Shore, MD, FACS
- Board B22** **Abstract 89: Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations.**  
First Author: Eunice Hankinson
- Board B23** **Abstract 90: Implementing comprehensive population-wide genomic testing in metastatic prostate cancer (mPCa): A real-world Canadian cohort study.**  
First Author: Hayley Nicole Roberts, MBBS, MPH, FRACP
- Board B24** **Abstract 91: Treatment and outcomes among patients with metastatic castrate resistant prostate cancer with an AR gene alteration: Analysis from the Kaiser Permanente Northern California Healthcare System.**  
First Author: Sachdev P. Thomas, MD
- Board B25** **Abstract 92: End-of-life treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Varun Nandakumar, MBBS
- Board B26** **Abstract 93: Durable outcomes in aggressive-variant prostate cancer treated with first-line carboplatin–docetaxel: A 10-year tertiary centre experience.**  
First Author: Ornjira Angkanawatana, MBChB
- Board C1** **Abstract 94: Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated between 2021-2025.**  
First Author: Gabriel Hooper, MD
- Board C2** **Abstract 95: Association between metabolic syndrome and treatment outcomes in metastatic prostate cancer: A retrospective cohort analysis.**  
First Author: Mohammed Shahait, MD
- Board C3** **Abstract 96: Quantifying the hidden burden of metastatic prostate cancer.**  
First Author: Bo-Sheng Wu, MD
- Board C4** **Abstract 97: Real-world treatment outcomes of advanced prostate cancer among Black compared to White men in the Medstar Health Network.**  
First Author: Sravya Jannapureddy, DO
- Board C5** **Abstract 98: Real-world utilization of tissue-free ctDNA monitoring in patients with prostate cancer.**  
First Author: Adam McLain Kase, MD
- Board C6** **Abstract 99: Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4).**  
First Author: Murilo De Almeida Luz, MD
- Board C7** **Abstract 100: Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting.**  
First Author: Rana R. McKay, MD, FASCO
- Board C8** **Abstract 101: Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure.**  
First Author: Micah Ostrowski, MD
- Board C9** **Abstract 102: Gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024).**  
First Author: Rana R. McKay, MD, FASCO
- Board C10** **Abstract 103: Overall survival (OS) in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors (ARPIs) with androgen-deprivation therapy (ADT) vs ADT alone for de novo metastatic castration-sensitive prostate cancer (mCSPC).**  
First Author: Martin W. Schoen, MD, MPH
- Board C11** **Abstract 104: Clinical outcomes in the real-world utilization of 177Lu-PSMA 617 in metastatic castrate-resistant prostate cancer.**  
First Author: Manish Kohli, MD
- Board C12** **Abstract 105: Discontinuation rates among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating novel androgen receptor inhibitors in oncology and non-oncology settings.**  
First Author: Hannah Dzimitrowicz McManus, MD

- Board C13 Abstract 106: Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.**  
First Author: Mehmet Asim Bilen, MD
- Board C14 Abstract 107: Prevalence of major adverse cardiac events in men with prostate cancer receiving androgen deprivation therapy in real-world clinical practice.**  
First Author: Andrew Warren Hahn, MD
- Board C15 Abstract 108: Baseline biochemical and clinical predictors of castration resistance and survival in metastatic hormone-sensitive prostate cancer treated with first-line androgen receptor pathway inhibitors: A multicenter real-world study.**  
First Author: Filipa Ribeiro Verdasca
- Board C16 Abstract 109: Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment.**  
First Author: Vaidehi Panchal, DO
- Board C17 Abstract 110: Real-world genomic analysis of chemerin in prostate cancer (PCa) and correlation with markers of immune infiltration and activation.**  
First Author: Parker Mathews, MD
- Board C18 Abstract 111: Treatment outcomes of patients (pts) with small cell or neuroendocrine carcinoma (SC/NE) of the prostate: A single-institution experience.**  
First Author: Christopher Eing Wee, MD
- Board C19 Abstract 112: Clinical characteristics and survival outcomes in veterans receiving radium-223 for metastatic castration-resistant prostate cancer.**  
First Author: Olivia Stojak
- Board C20 Abstract 113: Comparative outcomes of RANKL inhibitors versus bisphosphonates in metastatic prostate cancer with bone metastases: A TriNetX real-world analysis.**  
First Author: Saad Javaid, MD
- Board C21 Abstract 114: Comparison of quantitative functional RAD51 foci and genomic alterations in predicting PARPi response in mCRPC: A multicenter real-world study.**  
First Author: Bin Yang, MD, PhD
- Board C22 Abstract 115: Impact of androgen receptor pathway inhibitor (ARPI) dose reduction on overall survival of metastatic castration-resistant prostate cancer: A multi-centre retrospective study.**  
First Author: Ereny Samwel Poles Saad
- Board C23 Abstract 116: Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases.**  
First Author: Benedikt Lauer
- Board C24 Abstract 117: Post-operative pelvic lymph node radiation therapy in lymph node positive prostate cancer and mortality risk.**  
First Author: Mutlay Sayan, MD
- Board C25 Abstract 118: Aggressive variants and clinical patterns of progression in real-world metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Eva Lillo
- Board C26 Abstract 119: Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.**  
First Author: Manish Kohli, MD
- Board D1 Abstract 120: Severe acute kidney injury after abiraterone vs enzalutamide in advanced prostate cancer: A SEER–Medicare study.**  
First Author: Nikita Nikita, MD, MPH
- Board D2 Abstract 121: Real-world patient characteristics and treatment patterns among patients with metastatic castration-resistant prostate cancer treated with talazoparib plus enzalutamide in the US.**  
First Author: Pedro C. Barata, MD, MSc, FACP
- Board D3 Abstract 122: Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry.**  
First Author: Rana R. McKay, MD, FASCO
- Board D4 Abstract 123: Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer.**  
First Author: Martin W. Schoen, MD, MPH
- Board D5 Abstract 124: Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network.**  
First Author: Ejaz Shah, MD
- Board D6 Abstract 125: Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer.**  
First Author: Chiugo Okoye, MBBS
- Board D7 Abstract 126: Contemporary analysis of the prognostic significance of intraductal carcinoma of the prostate (IDC-P).**  
First Author: Ryan Michael Antar, BS
- Board D8 Abstract 127: Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.**  
First Author: Yashveer Chohan
- Board D9 Abstract 128: Predicting the risk of prostate cancer metastasis at diagnosis in the VA Health Care System from H&E slides of the prostate needle biopsies.**  
First Author: Beatrice Knudsen
- Board D10 Abstract 129: Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer.**  
First Author: Muhammad Umar Afzal, MBBS

- Board D11** Abstract 130: A prospective, randomized, cross-over trial to assess patient preference for goserelin microsphere versus goserelin implant in prostate cancer: Interim results of the GOMIMP study.  
First Author: Xuegang Wang
- Board D12** Abstract 131: Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey.  
First Author: Daniel J. George, MD, FASCO
- Board D13** Abstract 132: Association between prostate cancer and mental health: A comparison across cancer types using the Medical Expenditure Panel Survey, 2017–2022.  
First Author: Kamil Malshy, MD
- Board D14** Abstract 133: Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial.  
First Author: Brigida Anna Maiorano, MD
- Board D15** Abstract 134: Identifying and predicting non-cancer mortality risk in mHSPC following doublet therapy in the STAMPEDE trial.  
First Author: Omar El-Taji
- Board D16** Abstract 135: Adding metformin to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Quality of life (QoL) results from STAMPEDE.  
First Author: Omar El-Taji
- Board D17** Abstract 136: The association of androgen deprivation therapy with time to dementia: A large competing risk analysis.  
First Author: Michael J. Schell, PhD
- Board D18** Abstract 137: Safety profile of darolutamide + ADT compared to enzalutamide, apalutamide, and abiraterone in metastatic castration-sensitive prostate cancer: Results from the first safety matching-adjusted indirect comparison.  
First Author: Neal D. Shore, MD, FACS
- Board D19** Abstract 138: Renal outcomes following <sup>177</sup>Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Elizabeth Tchitchkan, BA, BS
- Board D20** Abstract 139: Prognostic significance of depressive symptoms in men with advanced prostate cancer (PC): Results from the IRONMAN registry.  
First Author: Eli Tran
- Board D21** Abstract 140: Effects of a diet high in omega-3 polyunsaturated fatty acids (PUFAs) on inhibition of soluble epoxide hydrolase (sEH) and mitigation of painful docetaxel-induced peripheral neuropathy in mice.  
First Author: Nicholas Mitsiades, MD, PhD
- Board D22** Abstract 141: Quality of life assessment during prostate cancer radionuclide therapy: Updated FACT-RNT psychometric evaluation.  
First Author: KD L. Jacobs, PhD
- Board D23** Abstract 142: SPPADE symptom burden and ePRO-based outcome prediction in patients with mCRPC treated with <sup>177</sup>Lu-PSMA-617 (LuPSMA).  
First Author: Miguel Muniz, MD
- Board D24** Abstract 143: Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.  
First Author: Abdul Baseet Arham, MBBS
- Board D25** Abstract 144: Bone fractures with androgen pathway inhibitors (ARPI) in patients (pts) with prostate cancer (PCa): A systematic review and network meta-analysis.  
First Author: Syed Arsalan Ahmed Naqvi, MD, MS
- Board D26** Abstract 145: Cardiovascular toxicity with androgen-receptor pathway inhibitors in metastatic prostate cancer: A meta-analysis of randomized trials.  
First Author: Muhammad Hussnain Sadiq, MBBS
- Board E1** Abstract 146: Development of cardiovascular disease risk factors in patients with prostate cancer initiating novel hormonal therapies (NHTs): Real world evidence.  
First Author: Dalia Kaakour, MD, MS, MPH
- Board E2** Abstract 147: Impact of abiraterone versus enzalutamide on depression and anxiety in hormone-sensitive prostate cancer (HSPC).  
First Author: Phoebe A. Tsao, MD, MSc
- Board E3** Abstract 148: EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).  
First Author: Albert Jang, MD
- Board E4** Abstract 149: A phase 1b/2 study of FOR46 in combination with enzalutamide (enza) in patients with metastatic castration resistant prostate cancer (mCRPC).  
First Author: Elise Y. Cai, MD, PhD
- Board E5** Abstract 150: ARTEMIS-003: A phase 2 study of HS-20093 (GSK5764227) in patients with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Xiaojie Bian
- Board E6** Abstract 151: ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients.  
First Author: Giulio Francolini, MD
- Board E7** Abstract 152: Efficacy and safety of the DLL3/CD3 T-cell engager obixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.  
First Author: Nil Navarro-Gorro

- Board E8** Abstract 153: 3-weekly docetaxel 75 mg/m<sup>2</sup> vs 2-weekly docetaxel 50 mg/m<sup>2</sup> in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial.  
First Author: Marc-Oliver Grimm, MD
- Board E9** Abstract 154: Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer.  
First Author: Qiang Dong, MD
- Board E10** Abstract 155: Impact of lutetium Lu 177 vipivotide tetraxetan on prostate cancer outcomes by race.  
First Author: Ramyashree Nyalakonda, DO
- Board E11** Abstract 156: A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).  
First Author: Edwin Melencio Posadas, MD, FACP
- Board E12** Abstract 157: PERSIAN trial (NCT03449719): Predictive features of complete biochemical response within a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.  
First Author: Giulio Francolini, MD
- Board E13** Abstract 158: Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial.  
First Author: Rana R. McKay, MD, FASCO
- Board E14** Abstract 159: Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer.  
First Author: Tsuyoshi Morita
- Board E15** Abstract 160: A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration.  
First Author: Alexander Dean Sherry, MD
- Board E16** Abstract 161: A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.  
First Author: Rahul Atul Parikh, PhD, MBBS
- Board E17** Abstract 162: Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4).  
First Author: Andrew J. Armstrong, MD, MS
- Board E18** Abstract 163: Safety data from UPLIFT: Phase I/II study of CDK4/6 inhibition with abemaciclib to upregulate PSMA expression prior to <sup>177</sup>Lu-PSMA-617 treatment in patients with metastatic castrate resistant prostate cancer (mCRPC).  
First Author: Talia Pikounis
- Board E19** Abstract 164: ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [<sup>225</sup>Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.  
First Author: Giuseppe Cardaci
- Board E21** Abstract 166: Clinical validity of FoundationOne CDx assay to identify *HRR*-positive or *BRCA*-positive mCSPC patients in the phase 3 AMPLITUDE study.  
First Author: Usha Singh, PhD
- Board E22** Abstract 167: Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON.  
First Author: Andrew Leonard Laccetti, MD, MS
- Board E23** Abstract 168: Clinical implications of prostate specific antigen (PSA) flare and response dynamics in TALAPRO-2: A post-hoc analysis.  
First Author: Steven Yip
- Board E24** Abstract 169: A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.  
First Author: Yuan Chang
- Board E25** Abstract 170: Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.  
First Author: Aanika Warner, MD, MPH
- Board E26** Abstract 171: Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study.  
First Author: Manish R. Patel, MD
- Board F1** Abstract 172: Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Junyong Dai
- Board F2** Abstract 173: Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone sensitive prostate cancer: An exploratory analysis of the STAMPEDE trials.  
First Author: Struan Gray, MBBSCh
- Board F3** Abstract 174: Pharmacokinetics and dosimetry of lutetium Lu 177 zadavotide guraXetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study.  
First Author: Frankis Almaguel, MD, PhD

- Board F4** **Abstract 175: Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: David R. Wise, MD, PhD
- Board F5** **Abstract 176: DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated mCRPC from a phase 1/2 study: Analyses according to prior treatment with lutetium 177 (177Lu)-PSMA-617.**  
First Author: Mark N. Stein, MD
- Board F6** **Abstract 177: Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.**  
First Author: Arun Azad, PhD, MBBS, FRACP
- Board F7** **Abstract 178: Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE *post hoc* analyses.**  
First Author: Fred Saad, MD, FRCS
- Board F9** **Abstract 180: Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration-sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data.**  
First Author: Alicia K. Morgans, MD, MPH, FASCO
- Board F10** **Abstract 181: The efficacy and safety of <sup>177</sup>Lu-PSMA-617 in Chinese patients with post-taxane metastatic castration-resistant prostate cancer: From a multicenter phase II study.**  
First Author: Dingwei Ye, MD
- Board F11** **Abstract 182: Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).**  
First Author: Himisha Beltran, MD, FASCO
- Board F12** **Abstract 183: A multicohort phase 2 trial of androgen deprivation therapy (ADT), docetaxel (DOCE), and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumors and DNA damage repair (DDR) alterations.**  
First Author: Xiao X. Wei, MD
- Board F13** **Abstract 184: Feasibility and outcomes of response-adapted and retreatment <sup>177</sup>Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Alireza Ghodsi, MD
- Board F14** **Abstract 185: Comparison of docetaxel triplet therapy with androgen receptor pathway inhibitor (ARPI) doublet in US veterans with metastatic hormone sensitive prostate cancer (mHSPC).**  
First Author: Abigail Chu
- Board F15** **Abstract 186: Impact of baseline hot flashes on sleep metrics during initial treatment in LIBERTAS clinical trial.**  
First Author: Arun Azad, PhD, MBBS, FRACP
- Board F16** **Abstract 187: A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis.**  
First Author: Justine Panian, MD
- Board F17** **Abstract 188: Metastatic lesion location and avidity on baseline PSMA PET/CT as predictor of duration of Lu177 treatment in men with metastatic castrate resistant prostate cancer.**  
First Author: Kailash M. Singh
- Board F18** **Abstract 189: Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.**  
First Author: Neal D. Shore, MD, FACS
- Board F19** **Abstract 190: Long-term clinical outcomes and genomic predictors of PSMA-PET/CT-guided cytoreductive progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.**  
First Author: Bin Yang, MD, PhD
- Board F20** **Abstract 191: Efficacy of rezvilutamide in preventing the flare phenomenon induced by GnRH agonists in newly diagnosed metastatic hormone-sensitive prostate cancer: An exploratory multicenter randomized controlled trial.**  
First Author: Yue Wu
- Board G1** **Abstract 192: Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.**  
First Author: Melissa Lauren Abel, MD
- Board G2** **Abstract 193: Redefining multimodal treatment in high-volume metastatic hormone-sensitive prostate cancer: Prospective evidence for robot-assisted cytoreductive prostatectomy following triplet systemic therapy.**  
First Author: Shangqian Wang
- Board G3** **Abstract 194: Estimated net benefit of talazoparib (TALA) + enzalutamide (ENZA) for patients (Pts) with mCRPC using a Q-TWiST analysis.**  
First Author: Neeraj Agarwal, MD, FASCO
- Board G4** **Abstract 195: Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.**  
First Author: Nobuaki Matsubara, MD
- Board G5** **Abstract 196: Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis.**  
First Author: William Padula, PhD
- Board G6** **Abstract 197: Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Axel Heidenreich, MD

- Board G7** Abstract 198: Switch androgen receptor pathway inhibitor strategies in metastatic castration-resistant prostate cancer: A meta-analysis of randomized trials.  
First Author: Akshit Chitkara, MD
- Board G8** Abstract 199: Shifting 177Lu-PSMA-617 upstream in mCRPC: A meta-analysis of randomized trials stratified by taxane exposure.  
First Author: Canan Dilay Dirican, MD
- Board G9** Abstract 200: Influence of body composition on the efficacy of chemotherapy in men with metastatic aggressive variant prostate cancer (AVPC).  
First Author: Kabir Grewal, MD
- Board G10** Abstract 201: Direct comparative and network meta analysis of PARP inhibitor and androgen receptor targeted therapies in first line mCRPC: Defining the optimal regimen among 8,997 patients.  
First Author: Shivam Chetankumar Patel, MD
- Board G11** Abstract 202: Overall survival in men with metastatic castration-resistant prostate cancer treated with olaparib or lutetium-177-PSMA-617 following prior systemic therapy.  
First Author: Shreyas Shirodkar, MD
- Board G12** Abstract 203: Metformin effects on renal function in mCRPC during PSMA radiopharmaceutical therapy (RPT): A retrospective analysis.  
First Author: Farzana Z. Ali, MD, PhD, MPH
- Board G13** Abstract 204: Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (the CIPHER trial).  
First Author: Atul Batra, MD, DM
- Board G14** Abstract 205: Clinical and demographic disparities in prostate cancer patients undergoing radical prostatectomy: A 20-year retrospective cohort study from the United States.  
First Author: Manas Pustake, MD
- Board G15** Abstract 206: Evaluation of toxicity profiles of next-generation androgen receptor pathway inhibitors in the geriatric population: Analysis of the FAERS (FDA Adverse Event Reporting System) database.  
First Author: Bugra Han Esen
- Board G16** Abstract 229: Effect of enzalutamide and bipolar androgen therapy on clonal hematopoiesis and clinical outcomes among men with metastatic castration resistant prostate cancer.  
First Author: Catherine Handy Marshall, MD, MPH
- Board G17** Abstract 207: Prognostic utility of neutrophil:lymphocyte ratio (NLR) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration resistant prostate cancer (mCRPC).  
First Author: Ronit Juthani, MD
- Board G19** Abstract 208: Patient-reported outcomes (PRO) from a dose-escalation and expansion trial of fractionated and multiple-cycle PSMA-targeted alpha radionuclide <sup>225</sup>Ac-J591.  
First Author: Tobechukwu Joseph Okobi, MD, MSc
- Board G20** Abstract 231: Development and validation of computational histology artificial intelligence (CHAI)-powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials (RCT).  
First Author: Neeraj Agarwal, MD, FASCO
- Board H1** Abstract 209: Efficacy and safety of Lu-177-DGUL in a phase 2 study of patients with metastatic castration-resistant prostate cancer (mCRPC).  
First Author: Chang Wook Jeong, MD, PhD
- Board H2** Abstract 210: Comprehensive genomic profiling in prostate cancer: Clinical relevance of BRCA1/2 pathogenic variants in the mCRPC.  
First Author: Fumihiko Urabe, MD, PhD
- Board H3** Abstract 232: Opening the black box: Biologic pathways underlying multimodal digital-pathology artificial intelligence in metastatic prostate cancer.  
First Author: Amol C. Shetty, PhD, MS
- Board H4** Abstract 211: Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: The KYUCOG-1901 study.  
First Author: Masaki Shiota, MD, PhD
- Board H5** Abstract 233: Adiposity and response to ADT ± AR pathway inhibitors (ARPI) in men with metastatic hormone-sensitive prostate cancer (mHSPC).  
First Author: Mitchell Boshkos, DO
- Board H6** Abstract 212: Investigation of the PORTOS gene expression signature and the benefit of docetaxel in the ECOG-ACRIN E3805 CHAARTED randomized trial.  
First Author: Shuang Zhao, MD
- Board H7** Abstract 234: TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer.  
First Author: Shiwei Liu
- Board H8** Abstract 213: Real-world evaluation of olaparib combined with novel hormone therapy in metastatic castration-resistant prostate cancer with intraductal adenocarcinoma.  
First Author: Qiyu Zhu, MD
- Board H9** Abstract 235: Plasma cell-free DNA methylation as a predictive biomarker for hormonal therapy response in advanced prostate cancer.  
First Author: Kyle S.Y. Miyazaki, MD
- Board H10** Abstract 214: Extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) as potential biomarkers of response to <sup>177</sup>Lu-PSMA-617.  
First Author: Albert Jang, MD
- Board H11** Abstract 236: Heterogeneity and synergistic inhibition of the poly(ADP-ribose) polymerase and androgen receptor signaling pathway in patients with metastatic castration-resistant prostate cancer.  
First Author: Bin Yang, MD, PhD

- Board H12 Abstract 215: Machine learning models combining <sup>68</sup>Ga-PSMA PET radiomics and clinical features to predict overall survival for mCRPC patients treated with <sup>177</sup>Lu-PSMA radioligand therapy.**  
First Author: Lucas Edouard
- Board H13 Abstract 237: Obesity-associated epigenetic remodeling under androgen deprivation therapy: Implications for cardiometabolic risk in prostate cancer.**  
First Author: Harikrishnan Hyma Kunhiraman, MD
- Board H14 Abstract 216: Effects of obesity on biphasic immune remodeling of CD45<sup>+</sup> circulating cells during androgen deprivation therapy in prostate cancer.**  
First Author: Harikrishnan Hyma Kunhiraman, MD
- Board H15 Abstract 238: Effects of 3 $\beta$ -HSD1 on back-conversion and androgen signaling in CRPC.**  
First Author: Masoud Bitaraf, MD
- Board H17 Abstract 239: Therapy-resistant subclones as drivers of progression in aggressive variant prostate cancer.**  
First Author: Quang Tran, PhD
- Board H18 Abstract 218: Liquid biopsy for detection of DDR gene alterations in metastatic prostate cancer (mPC): Diagnostic performance and clinical correlations.**  
First Author: Eleonora Lai, MD
- Board H19 Abstract 240: Clinical characteristics and molecular evolution of treatment-emergent small-cell/neuroendocrine prostate cancer in the era of doublet and triplet systemic therapy.**  
First Author: Nadeem Bilani, MD
- Board H20 Abstract 219: Homologous recombination deficiency signature (HRDsig) status in *BRCA1/2* wild type (*BRCA1/2wt*) clinically advanced prostate cancer (CAPC).**  
First Author: Georges Gebrael, MD
- Board H21 Abstract 241: Body composition metrics and clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-617.**  
First Author: Margo Gerke, BA
- Board H22 Abstract 220: Epigenomic alterations associated with androgen receptor pathway inhibitor response in metastatic castration-resistant prostate cancer.**  
First Author: Yuxin Yang, MS
- Board H23 Abstract 242: Non-invasive prostate cancer subtyping using 5hmC-sequencing of cell-free DNA.**  
First Author: Rensheng Wan, PhD
- Board H24 Abstract 221: Predictive value of a pathomics signature in *de novo* metastatic prostate cancer: An ancillary study of the PEACE-1 phase 3 trial.**  
First Author: Cedric Pobel, MD, PhD
- Board H25 Abstract 243: Homologous recombination repair (HRR) mutation in *de novo* metastatic hormone sensitive prostate cancer (mHSPC).**  
First Author: Nilan Patel
- Board H26 Abstract 222: Early prediction of PSA nadir in metastatic castration-sensitive prostate cancer with machine learning approaches.**  
First Author: Hayri Kagan Goren
- Board J1 Abstract 244: A prospective study exploring genomic correlates of clinical outcome in patients with metastatic castration-sensitive prostate cancer receiving enzalutamide.**  
First Author: Koji Hatano, MD
- Board J2 Abstract 223: Profiling BCRAness phenotype in public prostate cancer datasets without homologous repair gene mutations.**  
First Author: Federico Cayol, MD, MSc
- Board J3 Abstract 245: Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer.**  
First Author: Yi Cai, MD, PhD
- Board J4 Abstract 224: Examination of Decipher prostate genomic classifier in patients with *de novo* metastatic disease from a large scale real-world clinical and transcriptomic data linkage.**  
First Author: Shalini Moinji, MD
- Board J5 Abstract 246: Age as modifier of early proteomic remodeling after androgen deprivation therapy (ADT) in prostate cancer: Influence of innate immune/complement-ECM pathways.**  
First Author: Harikrishnan Hyma Kunhiraman, MD
- Board J6 Abstract 225: Cardiometabolic health's influence on outcomes in men with localized high-risk prostate cancer (HRPCa) treated with pre-operative ADT  $\pm$  AR pathway inhibition (ARPI).**  
First Author: Mitchell Boshkos, DO
- Board J7 Abstract 247: Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.**  
First Author: Robert Bruce Montgomery, MD
- Board J8 Abstract 226: Development of a putative liquid biopsy gene panel for predicting liver metastasis in castration-resistant prostate cancer.**  
First Author: Joshua Watson, PhD
- Board J9 Abstract 248: Gut microbiome (GMB) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair alterations (HRRm) treated with PARP inhibitor (PARPI) therapy.**  
First Author: Steven Yip
- Board J10 Abstract 227: The diversity and clinical relevance of germline DNA damage repair gene variants in 3005 patients with metastatic prostate cancer.**  
First Author: Sofie H. Tolmeijer, PhD, MSc
- Board J11 Abstract 249: Incidence and co-occurrence of targetable key genomic alterations (GenAlt) in metastatic prostate cancer (mPC): Preliminary results from the prostate cancer cohort of the FPG500 program.**  
First Author: Daniela Arduini, MD

- Board J12** **Abstract 228: Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Tara A. Seibert, MD
- Board J13** **Abstract 250: A liquid biopsy targeted proteomic assay to predict outcomes in castration resistant prostate cancer patients treated with 177Lu-PSMA-617.**  
First Author: Songyi Bae, PhD
- Board J14** **Abstract 251: Establishment and characterization of a panel of prostate adenocarcinoma XPD models representing naïve, chemotherapy- and radiotherapy-resistant patient populations.**  
First Author: Michael J. Wick, PhD
- Board J15** **Abstract 252: Prognostic and genomic implications of HER2 expression in metastatic prostate cancer.**  
First Author: Noemy Rodriguez Macias, MD
- Board J16** **Abstract 253: Prospective comparison of AR-V7 transcripts from whole blood and circulating tumor cells in castration-resistant prostate cancer patients undergoing treatment with androgen-receptor signaling inhibitors: The PEARL trial.**  
First Author: Matthias Heck
- Board J17** **Abstract 254: Plasma cfChIP-seq to predict cell surface target expression in neuroendocrine prostate cancer.**  
First Author: Rashad Nawfal, MD
- Board J18** **Abstract 255: Characterization of HER2 expression in prostate cancer compared with other solid tumors.**  
First Author: Rithika Rajendran, MD
- Board J19** **Abstract 256: Structural classification of FOXA1 alterations and their association with clinical outcomes in prostate cancer patients: A multi-institutional retrospective analysis.**  
First Author: Ryan Sun, MD
- Board J20** **Abstract 257: CCL21 as a treatment-linked prognostic biomarker in metastatic castration-resistant prostate cancer.**  
First Author: Paloma Galera, MD
- Board J21** **Abstract 258: Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving <sup>177</sup>Lu-PSMA-617.**  
First Author: Ali Arafa, MBChB
- Board J22** **Abstract 259: Optimizing neoadjuvant ADT duration prior to radiotherapy in high-risk prostate cancer: Rationale and clinical need.**  
First Author: Anmbreen Jamroze, PhD
- Board J23** **Abstract 260: Noninvasive fragmentomic profiling of plasma cell-free DNA (cfDNA) in metastatic prostate cancer (mPC): Associations with transcriptomic phenotypes and disease states.**  
First Author: Daniel Bsteh, PhD, MSc
- Board J24** **Abstract 261: Combining PSMA-PET metrics and circulating tumor cell RNA sequencing to predict LuPSMA response.**  
First Author: Kendra D. Marr, MD, PhD
- Board J25** **Abstract 262: Genetic ancestry and stage-specific differences in prostate cancer genomic alterations.**  
First Author: Nicholas Alexander Pickersgill, MD
- Board J26** **Abstract 263: Tumor microenvironmental NRG1 activation of HER3 as a driver of resistance to PI3K pathway inhibition in prostate cancer.**  
First Author: Kevin Shee, MD, PhD
- Board K1** **Abstract 264: Aggressive-variant prostate cancer features and therapeutic outcomes in patients with de-novo metastatic hormone-sensitive prostate cancer.**  
First Author: Qiyu Zhu, MD
- Board K2** **Abstract 310: A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET).**  
First Author: Jéssica Vasconcellos, MD
- Board K3** **Abstract 311: Diagnostic performance of <sup>18</sup>F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study.**  
First Author: Devaki Shiipa Surasi, MBBS
- Board K4** **Abstract 312: Effect of a one-time sensitive screening intervention on prostate cancer mortality: The STHLM3 randomized trial.**  
First Author: Chiara Micoli
- Board K5** **Abstract 313: Enhancing post-HIFU surveillance: Diagnostic performance of 18F-PSMA PET/CT and mpMRI for local prostate cancer recurrence.**  
First Author: Shayan Saeed, BA
- Board K6** **Abstract 314: Stockholm3-MRI population-based screening: Two-year outcomes comparing Stockholm3 and PSA.**  
First Author: Thorgerdur Palsdottir, PhD
- Board K7** **Abstract 315: Inherited risk for prostate cancer (PCa): Following the natural history of men with increased genetic risk using multiparametric MRI (mpMRI).**  
First Author: Anna Couvillon, FNP
- Board K8** **Abstract 316: Predictive capability of combining ExoDx (EPI) and pre-biopsy prostate MRI in detecting clinically significant prostate cancer in African American men.**  
First Author: Rollins Turner, BS
- Board K9** **Abstract 317: Prostate cancer screening in a geriatric population.**  
First Author: Somya Bhatnagar, MD
- Board K10** **Abstract 318: Micro-ultrasound compared with MRI-targeted biopsy in detecting clinically significant prostate cancer: Systematic review and meta-analysis.**  
First Author: Caio Suartz, MD

- Board K11 Abstract 319: Is it time to redefine the Phoenix criterion for biochemical failure in the era of PSMA PET/CT?**  
First Author: Prantik Das, MD
- Board K12 Abstract 320: Comparison of multiparametric prostate MRI (mpMRI) vs. positive biopsy cores on risk of adverse pathologic outcomes after radical prostatectomy (RP) in Gleason grade group (GG) 2 prostate cancer.**  
First Author: Sam Kwon, BA
- Board K13 Abstract 321: The clinical impact of germline variants in DNA repair genes in patients who underwent curative surgery for localized prostate cancer.**  
First Author: Giovanni Lughezzani, MD
- Board K14 Abstract 322: Rethinking germline testing in localized prostate cancer: Prevalence of germline variants and association with Gleason score and NCCN risk grouping.**  
First Author: Adam Cole, MD
- Board K15 Abstract 323: Four-year outcomes of a genetic-based screening protocol for prostate cancer: Unveiling the Italian paradox.**  
First Author: Vittorio Fasulo, MD
- Board K16 Abstract 324: Biopsy patterns following high intensity focused ultrasound as assessed by CAPRA score.**  
First Author: Cameron Agapito, BA
- Board K17 Abstract 337: From innovation to evidence: Trends in AI/ML clinical trials in GU oncology, 2010-2025.**  
First Author: Henry Kazunaru Litt, MD
- Board K18 Abstract 338: Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE).**  
First Author: Neal D. Shore, MD, FACS
- Board K19 Abstract 339: Impact of piflufolastat F18 imaging on disease management for prostate cancer patients: Observations from the PYLARIFY Registry study.**  
First Author: Gordon Andrew Brown, DO
- Board K20 Abstract 340: The impact of the 2025 NCCN update in defining very high-risk prostate cancer on surgical outcomes after robot-assisted radical prostatectomy: A retrospective cohort analysis.**  
First Author: Noriyoshi Miura, MD, PhD
- Board K21 Abstract 341: Trends in high grade prostate cancer at diagnosis in the United States from 2004-2022.**  
First Author: Aparna Krishnan
- Board K22 Abstract 342: Salvage radiotherapy after radical prostatectomy in a Japanese cohort: Analysis from the MICAN study.**  
First Author: Kosuke Seto, MD
- Board K23 Abstract 343: Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP).**  
First Author: Neal D. Shore, MD, FACS
- Board K24 Abstract 344: Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.**  
First Author: Christopher J.D. Wallis, MD, PhD
- Board K25 Abstract 345: Association between preoperative glycemic control and outcomes after radical prostatectomy.**  
First Author: Rishabh Simhal, MD
- Board K26 Abstract 346: Polypharmacy and potential drug-drug interactions with novel androgen receptor signaling inhibitors (ARSIs) in patients (pts) with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) in a real-world setting.**  
First Author: Edwin Albert D Souza, MD
- Board L1 Abstract 347: The practice of active surveillance for prostate cancer: Trends, variation, and quality within a large national health system.**  
First Author: John R. Bihn, BA
- Board L2 Abstract 348: Predictive value of Gleason pattern 4 length on adverse surgical pathology and oncologic outcomes.**  
First Author: Theodoros Karanikolas
- Board L3 Abstract 349: Pelvic lymph node risk stratification in prostate cancer: A machine learning approach toward a predictive nomogram.**  
First Author: Andres Felipe Gutierrez
- Board L4 Abstract 350: Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.**  
First Author: Michael Leapman, MD
- Board L5 Abstract 351: Long-term oncological outcomes of prostate cancer upgrading following robot-assisted radical prostatectomy.**  
First Author: Milagros Secin
- Board L6 Abstract 352: Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.**  
First Author: Muhammad Ali Khan, MBBS
- Board L7 Abstract 353: Real-world determinants of testosterone recovery following androgen deprivation therapy in patients with localized prostate cancer.**  
First Author: Sarika Gurnani, MD
- Board L8 Abstract 354: Early-onset prostate cancer: A time series analysis of age-stratified trends.**  
First Author: Charmi Bhanushali, MBBS
- Board L9 Abstract 355: Prospective evaluation of sexual function over 5 years in patients with localized prostate cancer treated with carbon-ion radiotherapy.**  
First Author: Yoshiyuki Miyazawa, MD, PhD
- Board L10 Abstract 356: Plant-based dietary indices and quality of life in men with prostate cancer.**  
First Author: Simran Sandhu, MPH, MS

- Board L11** **Abstract 357: Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer.**  
First Author: Renthony Wilson Jr
- Board L12** **Abstract 358: Cardio-kidney-metabolic syndrome and prostate cancer: Prognostic significance of higher stages for cardiovascular morbidity and mortality.**  
First Author: Tarek Nahle, MD
- Board L13** **Abstract 359: Germline radiosensitivity biomarker for radiation-induced GU toxicity following radiation therapy in localized prostate cancer (GARUDA): Two-year outcomes of a phase II clinical trial.**  
First Author: Jesus Eduardo Juarez Casillas, MD
- Board L14** **Abstract 360: Differential quality of life (QoL) with novel hormonal therapy (NHT) in metastatic castration-sensitive prostate cancer (mCSPC): A network meta-analysis of randomized clinical trials.**  
First Author: Muhammad Uzair Sarfraz, MBBS
- Board L15** **Abstract 361: Randomized pilot trial of pre-visit patient education as preparation for decision making in newly diagnosed prostate cancer (PrepDM).**  
First Author: Kshitij Pandit, MD
- Board L16** **Abstract 362: Interim safety analysis of a randomized phase II trial comparing pembrolizumab with radiation versus pembrolizumab, olaparib, and radiation in localized high risk prostate cancer.**  
First Author: Zin W. Myint, MD
- Board L17** **Abstract 363: A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer.**  
First Author: Gwenaelle Gravis, MD
- Board L18** **Abstract 364: SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP).**  
First Author: Piet Dirix, MD, PhD
- Board L19** **Abstract 365: The impact of rising PSA during salvage radiotherapy post radical prostatectomy on relapse.**  
First Author: Scott Tyldesley, MD, FRCPC
- Board L20** **Abstract 366: The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with histologic variants of prostate cancer.**  
First Author: Zehua Tan
- Board L22** **Abstract 368: CT- vs 1.5T MR-guidance in salvage radiotherapy of locally recurrent prostate cancer after radical prostatectomy.**  
First Author: Jina Kim
- Board L23** **Abstract 369: Perioperative outcomes from a randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robot-assisted radical prostatectomy (RARP).**  
First Author: Ruben Olivares, MD
- Board L24** **Abstract 370: A feasibility trial investigating inductive apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer: First results of the prospective phase II INDUCTA study.**  
First Author: Matthias Saar, MD
- Board L25** **Abstract 371: Efficacy, safety, and cost-effectiveness of reduced vs. full initial dose androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board L26** **Abstract 372: Angelica herbal supplement AGN-Cogni.Q acute dose safety and pharmacokinetics (PK) dose-response in prostate cancer patients.**  
First Author: Monika Joshi, MD
- Board M1** **Abstract 373: Impact of intraoperative frozen section analysis (NeuroSAFE) on oncologic and functional outcomes after radical prostatectomy: A systematic review and meta-analysis.**  
First Author: Caio Suartz, MD
- Board M2** **Abstract 374: Role of urinary exosomal FAM153C-RPL19 in detection and risk stratification of prostate cancer: A multicentre Chinese cohort study.**  
First Author: Bisheng Cheng
- Board M3** **Abstract 375: MRI-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial.**  
First Author: Yongbing Cheng
- Board M4** **Abstract 376: Prostate cancer: Correlating the clinical phenotype to the genotype.**  
First Author: Hadas Dresler, MD
- Board M5** **Abstract 377: Deep spatial analysis of the tumor-immune interface in localized prostate cancer.**  
First Author: Aishwarya Atmakuri, BS
- Board M6** **Abstract 378: Association of a post-prostatectomy digital pathology-based multimodal artificial intelligence (MMAI) biomarker with nodal and extrapelvic metastasis on PET/CT at the time of biochemical recurrence and event-free survival following salvage radiotherapy.**  
First Author: Sagar Anil Patel, MD
- Board M7** **Abstract 379: Microplastics and prostate cancer.**  
First Author: Stacy Loeb, MD, PhD, MS
- Board M8** **Abstract 380: Insulin pathway changes in localized prostate cancer: A multi-institutional analysis.**  
First Author: Evan Adler, MD
- Board M9** **Abstract 381: Prognostic value and clinical utility of a six-gene signature for aggressive prostate cancer among clinically low or intermediate risk patients.**  
First Author: Agnieszka Krzyzanowska
- Board M10** **Abstract 382: Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.**  
First Author: Xiaolei Shi, MD, PhD

- Board M11 Abstract 383: Synergistic efficacy of gedatolisib and darolutamide in prostate cancer to overcome resistance to androgen-targeted therapy.**  
First Author: Stefano Rossetti, PhD
- Board M12 Abstract 384: Enhancing the molecular assessment of MRI targeted prostate biopsies utilizing near real time stimulated Raman histology and artificial intelligence.**  
First Author: Takeshi Namekawa
- Board M13 Abstract 385: Spatially resolved HER2 and AR expression in prostate cancer and its implications for HER2 as a distinct therapeutic target.**  
First Author: Leanne Woods-Burnham, PhD
- Board M14 Abstract 386: Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial.**  
First Author: Vishal Ramesh Dhere, MD
- Board M15 Abstract 387: Clinical outcomes of patients with grade group 1 prostate cancer with extraprostatic extension: Results from up to 25 years of follow-up.**  
First Author: Gagan Fervaha, MD, PhD
- Board M16 Abstract 388: Concordance between clinical, genomic, and AI-based risk stratification in prostate cancer.**  
First Author: Bruno R. Bastos, MD
- Board M17 Abstract 389: Remodeling of the periprostatic adipose microenvironment in aggressive prostate cancer: Insights from a multi-institutional atlas-based geometric analysis.**  
First Author: Sena Azamat
- Board M18 Abstract 390: PAM50 intrinsic subtyping and Decipher genomic classifier in biochemically recurrent prostate cancer after prostatectomy: Implications for ADT selection.**  
First Author: Jonathan David Tward, MD, PhD, FASTRO
- Board M20 Abstract 392: FAP+FN1+CAV1+ cancer-associated fibroblast subtype and its association with aggressive behavior in localized prostate cancer.**  
First Author: Mohammed Shahait
- Board M21 Abstract 393: Is there an opportunity for checkpoint inhibition in MYC amplified castration resistant prostate cancer?**  
First Author: Kriti Ahuja, MBBS
- Board M22 Abstract 394: The Prolaris test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis.**  
First Author: Steven Monda, MD, MSCI
- Board M23 Abstract 395: Can clinico-genomic characterization reveal more aggressive prostate cancer among older patients with lower Gleason grade groups?**  
First Author: Sibtain Mustafa, MD
- Board M24 Abstract 396: Transcriptomic characterization of prostate cancer in patients with HIV infection.**  
First Author: Michael Leapman, MD
- Board M25 Abstract 397: Patient-derived primary prostate cancer epithelial cultures for studying prostate cancer cell evolution under hypoxia.**  
First Author: Robert G. Bristow, MD, PhD
- Board M26 Abstract 398: Histologic predictors of clinically significant biochemical recurrence and PSA kinetics after radical prostatectomy.**  
First Author: Kristina Dortche
- Board N1 Abstract 399: An artificial intelligence–digital pathology algorithm to predict outcomes in a cohort of men diagnosed with prostate cancer within a low resource setting.**  
First Author: Samantha Webking, MD
- Board N2 Abstract 400: Spatially mapping the prostate cancer tumor microenvironment to reveal immune cell drivers of aggressive disease.**  
First Author: William S. Chen, MD
- Board N3 Abstract 401: Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial.**  
First Author: Tim RTD Oliver, MD
- Board N4 Abstract 402: Integrating genomic prognostic and hallmark signatures from Decipher GRID to predict adverse outcomes in men on active surveillance for prostate cancer.**  
First Author: Kevin Shee, MD, PhD

11:30 AM-12:45 PM and 5:45 PM-6:45 PM  
**Trials in Progress Poster Session A: Prostate Cancer**  
Level 1, West Hall

**Posters by Topic**

**Prostate Cancer - Advanced**

- Diagnostics and Imaging: N5
- Quality of Care/Quality Improvement: N6, N7
- Real-World Evidence: N8
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: N9, N10
- Therapeutics: N11-N26, P1-P16

**Prostate Cancer - Localized**

- Diagnostics and Imaging: P17
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: P18-P21
- Therapeutics: P22-P26

**Board N5** **Abstract TPS269: AMPLIFY: A phase 3 study of <sup>64</sup>Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.**  
First Author: Neal D. Shore, MD, FACS

**Board N6** **Abstract TPS270: Improving delivery of prostate cancer germline testing at the Department of Veterans Affairs: A cluster-randomized trial.**  
First Author: Daniel H. Kwon, MD

**Board N7** **Abstract TPS271: SOLACE: A phase 1 pharmacokinetic, dosimetry, safety, and dose optimization study for a single dose of <sup>153</sup>Sm-DOTMP to treat metastatic bone pain.**  
First Author: Ebrahim S. Delpassand, MD

**Board N8** **Abstract TPS272: Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial.**  
First Author: Renato Naito, MD, PhD

**Board N9** **Abstract TPS273: Intermittent fasting in prostate cancer patients receiving androgen deprivation therapy.**  
First Author: Roberto Pili, MD

**Board N10** **Abstract TPS274: Internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors: The iLIVE trial.**  
First Author: Kerri M. Winters-Stone, PhD, MS

**Board N11** **Abstract TPS275: A phase II study of luxdegalutamide in combination with abiraterone in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Rana R. McKay, MD, FASCO

**Board N12** **Abstract TPS276: Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer.**  
First Author: Wassim Abida, MD, PhD

**Board N13** **Abstract TPS277: Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).**  
First Author: Yu-Wei Chen, MD, MS

**Board N14** **Abstract TPS278: The LuxAR-02 phase II study of luxdegalutamide in combination with [<sup>177</sup>Lu] Lu-PSMA-617 in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer (mCRPC).**  
First Author: Daniel P. Petrylak, MD

**Board N15** **Abstract TPS279: SPECTRA study: A phase II trial of supraphysiological androgen to enhance treatment activity with DNA-damaging agents in men with metastatic castration resistant prostate cancer (mCPRC).**  
First Author: Gabrielle Paras, MD

**Board N16** **Abstract TPS280: Phase 2 expansion study of <sup>212</sup>Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial.**  
First Author: Aaron Richard Hansen, MBBS, FRACP

**Board N17** **Abstract TPS281: A phase 1 study of docetaxel in combination with 177-lutetium-PSMA-I&T in patients with metastatic castration-resistant prostate cancer.**  
First Author: Jose Mauricio Mota, MD, PhD

**Board N18** **Abstract TPS282: ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [<sup>225</sup>Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.**  
First Author: Giuseppe Cardaci

**Board N19** **Abstract TPS283: Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate cancer.**  
First Author: Jabra Zarka, MD

**Board N20** **Abstract TPS284: MEVPRO-3: Phase III trial of mevrometostat plus enzalutamide (versus placebo plus enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC).**  
First Author: Neeraj Agarwal, MD, FASCO

**Board N21** **Abstract TPS285: A study of GSK5458514 administered alone or in combination with other anticancer agents in patients with prostate cancer.**  
First Author: Benjamin Garmez, MD

**Board N23** **Abstract TPS287: A phase I clinical trial of autologous gamma delta T cells genetically engineered with a chimeric receptor to target the prostate stem cell antigen in patients with metastatic castration-resistant prostate cancer.**  
First Author: Jingsong Zhang, MD, PhD

**Board N24** **Abstract TPS288: OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.**  
First Author: Umang Swami, MD, FASCO

- Board N25** **Abstract TPS289: Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.**  
First Author: Brandon Robert Mancini, MD, MBA, FACRO
- Board N26** **Abstract TPS290: ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).**  
First Author: Deepak Kilari, MD
- Board P1** **Abstract TPS291: A pragmatic phase 2 trial of locally ablative therapy in oligo-progressive genitourinary (GU) tumors: LAYOVER**  
First Author: Amisha Singh, MD
- Board P2** **Abstract TPS292: A phase II study of lutetium-177 DOTATATE in metastatic prostate cancer with neuroendocrine differentiation.**  
First Author: John M. Floberg, MD, PhD
- Board P3** **Abstract TPS293: Dose optimisation and PSMA receptor intensification with <sup>177</sup>Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial.**  
First Author: Louise Emmett, MD, MChB, FRACP
- Board P4** **Abstract TPS294: IDEate-Prostate01: A phase 3, randomized, open-label study of ifinatumab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer.**  
First Author: Rana R. McKay, MD, FASCO
- Board P5** **Abstract TPS295: Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Bilal Ahmed Siddiqui, MD
- Board P6** **Abstract TPS296: Nezastomig (anti-PSMAxCD28) with or without cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study.**  
First Author: Bilal Ahmed Siddiqui, MD
- Board P7** **Abstract TPS297: IDEate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatumab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer.**  
First Author: Johann S. De Bono, MD, PhD, MB, MSc
- Board P8** **Abstract TPS298: OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy.**  
First Author: Evan Y. Yu, MD
- Board P9** **Abstract TPS299: OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.**  
First Author: Karim Fizazi, MD, PhD
- Board P10** **Abstract TPS300: Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer.**  
First Author: Neal Shore
- Board P11** **Abstract TPS301: TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).**  
First Author: Andrew J. Armstrong, MD, MS
- Board P12** **Abstract TPS302: TulmiSTAR-02: A phase I/II open-label study of dose escalation and expansion of tulmimetostat in combination with darolutamide versus darolutamide, and tulmimetostat with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).**  
First Author: Neal D. Shore, MD, FACS
- Board P13** **Abstract TPS303: CARPET trial: A phase II trial evaluating trastuzumab deruxtecan in metastatic castration-resistant prostate cancer.**  
First Author: Rithika Rajendran, MD
- Board P16** **Abstract TPS304: A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Adam Sharp, MD, PhD, MRCP
- Board P17** **Abstract TPS406: Phase 3 study of <sup>68</sup>Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BIPASS).**  
First Author: Clint D. Bahler
- Board P18** **Abstract TPS407: Determining individual preferences for gynecomastia avoidance among men with prostate cancer: A qualitative study.**  
First Author: Anthony M. Joshua, PhD, FRACP, MBBS
- Board P19** **Abstract TPS408: Bladder full or empty for pelvic radiation therapy (BEFORE): A multi-center randomized controlled trial.**  
First Author: Anna Dornisch, MD
- Board P20** **Abstract TPS409: Radiation dose tailoring guided by enhanced targeting (RadTARGET): A multi-center randomized controlled trial.**  
First Author: Anna Dornisch, MD
- Board P21** **Abstract TPS410: A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: Protocol for a hybrid type I efficacy implementation trial.**  
First Author: Kerri M. Winters-Stone, PhD, MS

**Board P22 Abstract TPS411: Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO).**

First Author: Giulio Francolini, MD

**Board P23 Abstract TPS412: Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02).**

First Author: Rana R. McKay, MD, FASCO

**Board P24 Abstract TPS413: Evaluation of the safety and efficacy of daily oral *Angelica gigas* Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial).**

First Author: Monika Joshi, MD

**Board P25 Abstract TPS414: A randomized trial of neoadjuvant leuprorelin, darolutamide, or both prior to radical prostatectomy for intermediate- or high-risk prostate cancer.**

First Author: Fernando de Moura

**Board P26 Abstract TPS415: High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo.**

First Author: Mohammad O. Atiq, MD

11:30 AM-12:45 PM and 4:45 PM-5:45 PM

**Poster Session B: Prostate Cancer and Urothelial Carcinoma**

Level 1, West Hall

**Posters by Topic**

**Prostate Cancer - Advanced**

- Health Care Access and Outcomes: A1-A12
- Quality of Care/Quality Improvement: A13-A22
- Other: A23-A26

**Prostate Cancer - Localized**

- Health Care Access and Outcomes: B1-B7
- Quality of Care/Quality Improvement: B8-B12
- Other: B13-B15

**Urothelial Carcinoma**

- Diagnostics and Imaging: B16-B20
- Health Care Access and Outcomes: B21-B26, C1-C10
- Quality of Care/Quality Improvement: C11-C17
- Real-World Evidence: C18-C26, D1-D26, E1-E10
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: E11-E26, F1-F3
- Therapeutics: F4-F20, G1-G20, H1-H17
- Translational Research, Tumor Biology, Biomarkers, and Pathology: H18-H26, J1-J26, K1-K26, L1-L20
- Other: L21-L26, M1-M6

- Board A1** **Abstract 38: Tobacco use and survival among veterans with metastatic prostate cancer.**  
First Author: Simran Doshi
- Board A2** **Abstract 39: Racial disparities and trends in the in-hospital mortality for malignant prostate cancer.**  
First Author: Jugraj Singh, MD
- Board A3** **Abstract 40: Determinants of treatment intensification in metastatic hormone-sensitive prostate cancer: Institutional vs patient-level factors in a diverse UK multicentre cohort.**  
First Author: Birth-Lynn Tyers, MBChB
- Board A4** **Abstract 41: Clinical and cost impact of cabazitaxel versus lutetium-177 vipivotide tetraxetan (Lu-PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC).**  
First Author: Braydon Nault
- Board A5** **Abstract 42: Temporal and racial patterns in prostate cancer stage migration following USPSTF PSA screening policy changes: A SEER 2005–2022 analysis.**  
First Author: Ecem Kalemoglu, MD, PhD
- Board A6** **Abstract 43: Availability of clinical trials investigating prostate cancer (PC) in the United States (US).**  
First Author: Benjamin Mercier, BSc
- Board A7** **Abstract 44: Representation of Latin American oncologists in oral sessions at the ASCO Genitourinary Cancers symposium: A five-year review (2021–2025).**  
First Author: Daniel Vargas Pivato de Almeida, MD
- Board A8** **Abstract 45: First-line (1L) systemic treatment patterns and impact of race in metastatic castration-resistant prostate cancer (mCRPC): A nationwide Veterans Affairs (VA) study.**  
First Author: Brianna Stanfield, MS, MSc

- Board A9** **Abstract 46: Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.**  
First Author: M. Neil Reaume, MD, MSc, FRCPC
- Board A10** **Abstract 47: Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone.**  
First Author: Minkyoungh Yoo, PhD
- Board A11** **Abstract 48: Trends in advanced-stage prostate cancer over the last decade: Analysis from the National Cancer Database (NCDB).**  
First Author: Laura Meili Linville, MD, MS
- Board A12** **Abstract 49: Real-world treatment transitions and healthcare resource utilization in patients with metastatic castration-resistant prostate cancer in Colombia.**  
First Author: Ray Manneh, MD
- Board A13** **Abstract 50: Improving quality of life measures for use in shared decision-making in advanced prostate cancer.**  
First Author: Gunhild Von Amsberg, MD
- Board A14** **Abstract 51: Quality improvement initiative to increase osteoporosis screening in patients with prostate cancer on long-term androgen deprivation therapy.**  
First Author: Fabian Johannes Bolte, MD
- Board A15** **Abstract 52: Cardiovascular risk evaluation in men with prostate cancer study (CARE-PC): Pilot study to assess patient awareness and risk mitigation.**  
First Author: George Mo, MD
- Board A16** **Abstract 53: Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial.**  
First Author: Alicia K. Morgans, MD, MPH, FASCO
- Board A17** **Abstract 54: A rules-based AI triage system to identify NCCN-indicated genetic testing in prostate cancer: A performance analysis.**  
First Author: Mitchell Singstock, MD
- Board A18** **Abstract 55: Non-cancer causes of death in patients with hormone-sensitive prostate cancer.**  
First Author: Clara Rodrigo
- Board A19** **Abstract 56: Assistance of a large language model-based AI agent in preoperative communication for reduction of prostate cancer patients' anxiety and clinicians' burden: A prospective, randomized, single-blinded, phase II trial.**  
First Author: Zheng Liu, PhD
- Board A20** **Abstract 57: Physician perspectives on the implementability of a cardiovascular risk score for prostate cancer: A PRISM-guided evaluation.**  
First Author: Harikrishnan Hyma Kunhiraman, MD

- Board A21** **Abstract 58: Skeletal-related event impact on prostate cancer mortality in the older population in the US: A 24-year trend regression analysis.**  
First Author: Mahnoor Sukaina, MBBS
- Board A22** **Abstract 59: Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, Canada.**  
First Author: Christopher J.D. Wallis, MD, PhD
- Board A23** **Abstract 265: POSTER: Evaluating the impact of virtual peer-led support groups on prostate cancer survivorship—The AnCan experience.**  
First Author: John Antonucci, MD
- Board A24** **Abstract 266: Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer.**  
First Author: Monica V. Meeks, MD
- Board A25** **Abstract 267: Imaging meets genomics in treatment-naïve prostate cancer: SUVmax on prostate-specific membrane antigen (PSMA) PET as a biomarker of genomic classifier risk.**  
First Author: Sophia Coraci, BS
- Board A26** **Abstract 268: Assessing the impact of cardiovascular disease and ADT on survival disparities in prostate cancer.**  
First Author: Camille Ragin
- Board B1** **Abstract 325: Trends in prostate cancer mortality after the 2012 USPSTF PSA guideline: Comparisons with kidney cancer and racial disparities.**  
First Author: Farzeen Fatma Syed, MD, MBBS
- Board B2** **Abstract 326: Prostate cancer in patients with HIV: A multisite retrospective cohort study.**  
First Author: Fiona Wardrop, BS
- Board B3** **Abstract 327: County-level educational attainment and long-term outcomes in older men with prostate cancer: A SEER-Medicare 2009–2017 study.**  
First Author: Viraj R. Shah, MBBS
- Board B4** **Abstract 328: Patterns and predictors of online cancer information seeking among urological cancer survivors.**  
First Author: Xian Zhang
- Board B5** **Abstract 329: Impact of social environment on prostate cancer care across the clinical risk spectrum for Black men treated in community settings.**  
First Author: Jason L. Goodloe, MD
- Board B6** **Abstract 330: The nature of progression on active surveillance for grade group 2 prostate cancer.**  
First Author: Kevin Shee, MD, PhD
- Board B7** **Abstract 331: Predictors of early termination in phase 2–3 genitourinary oncology trials: A two-decade analysis of clinicaltrials.gov.**  
First Author: Kamil Malshy, MD
- Board B8** **Abstract 332: Impact of pre-visit educational videos on clinic efficiency for prostate cancer radiation oncology consultations.**  
First Author: Samantha Ashley Martin, BA
- Board B9** **Abstract 333: Patterns of management and multidisciplinary care in high/very high and intermediate risk localized prostate cancer: A population-based study in Ontario, Canada.**  
First Author: Christopher J.D. Wallis, MD, PhD
- Board B10** **Abstract 334: Evaluating frailty and quality of life in low-income, uninsured men with prostate cancer.**  
First Author: Eshwin Varghese
- Board B11** **Abstract 335: Comparing concordance of prostate cancer clinical trials and disease incidence in the United States in 2021 and 2022.**  
First Author: Allison Carroll, BS
- Board B12** **Abstract 336: Population-level trends in radiation treatment of low-risk prostate cancer.**  
First Author: Varshini Odayar, MS
- Board B13** **Abstract 403: Prostate cancer screening uptake and predictors of elevated prostate-specific antigen levels in Southwestern Nigeria.**  
First Author: Ayodeji Oluwatobi Ojetunde, MSc
- Board B14** **Abstract 404: Use of active surveillance in young men with low-risk prostate cancer.**  
First Author: Joseph Manus, BS
- Board B15** **Abstract 405: Artificial intelligence (AI)-assisted eligibility screening for prostate cancer clinical trial matching.**  
First Author: Phu N. Tran, PhD
- Board B16** **Abstract 640: Multimodal integration of VI-RADS, radiomics, and deep learning features for prediction of pathology and prognosis in bladder cancer.**  
First Author: Shunsuke Ikuma, PhD
- Board B17** **Abstract 641: Inferring optimal MTAP homozygous loss (homozygous deletion) detection in urothelial cancer: Prevalence and co-alterations based upon treatment exposure and anatomical location.**  
First Author: Abhishek Tripathi, MD
- Board B18** **Abstract 642: Effect of digital Ki67-based risk modeling on prognostic precision in non-muscle-invasive bladder cancer and high-risk subsets in mixed-grade tumors.**  
First Author: Jane K. Nguyen, MD, PhD
- Board B19** **Abstract 643: RNA based liquid biopsy testing of urine to predict pathological complete response to radiomolecular instillation NAC therapy before surgery: The Bladder BRIDGister experience.**  
First Author: Ralph M. Wirtz, PhD
- Board B20** **Abstract 644: Prospective multicenter development and external validation of a narrow-band imaging based prediction model for malignancy risk in bladder lesions.**  
First Author: Xiaoyi Zhang, MD

- Board B21 Abstract 645: Healthcare utilization and expenditure burden in bladder cancer: A nationally representative analysis (MEPS 2015–2022).**  
First Author: Kamil Malshy, MD
- Board B22 Abstract 646: Inclusion of patients from Latin America in pivotal trials in genitourinary (GU) and cutaneous malignancies.**  
First Author: Erika Martinez, MD
- Board B23 Abstract 647: Patterns of neoadjuvant chemotherapy (NAC) use in stage II-III bladder cancer: A California Cancer Registry (CCR) analysis.**  
First Author: Mamta Parikh, MD, MS
- Board B24 Abstract 648: Cost-effectiveness analysis of new perioperative treatment regimens for muscle-invasive bladder cancer in Germany.**  
First Author: Constantin Rieger, MD, MBA
- Board B25 Abstract 649: Temporal trends in mortality from bladder cancer with chronic kidney disease in the United States, 1999–2023: A population-based analysis.**  
First Author: Maryam Abid, MD, MBBS, MRCP
- Board B26 Abstract 650: Association of coexisting amyloidosis with survival outcomes in bladder cancer: A real-world cohort study.**  
First Author: Uchenna Amaechi
- Board C1 Abstract 651: Racial and ethnic disparities in variant histology bladder cancer: Insights from SEER 2000–2021.**  
First Author: Canan Dilay Dirican, MD
- Board C2 Abstract 652: Regional variations in bladder cancer (BC) clinical trial availability within the United States (US).**  
First Author: Koral U. Shah, MD
- Board C3 Abstract 653: Any regression of tumor (ART) to discriminate improvement in overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) receiving PD1/L1 inhibitors who exhibit stable disease (SD) by RECIST1.1.**  
First Author: Bakr Alhayek, MD
- Board C4 Abstract 654: Clinical and social determinants of definitive surgical management in bladder cancer: A two-decade population-based analysis from the United States.**  
First Author: Manas Pustake, MD
- Board C5 Abstract 655: Patient and trial design factors influencing participation in prospective bladder and kidney cancer clinical trials.**  
First Author: Catherine Graham
- Board C6 Abstract 656: National trends and disparities in bladder cancer mortality associated with tobacco use between 1999 and 2020.**  
First Author: Amro Ali, MD
- Board C7 Abstract 657: Demographic and socioeconomic disparities in early-onset vs. late-onset bladder cancer: A cross-sectional study in the NIH All of Us research program.**  
First Author: Xiaoyi Zhang, MD
- Board C8 Abstract 658: Twenty-five years of bladder cancer mortality in the U.S. (1999–2024).**  
First Author: Athar Nawab, MD
- Board C9 Abstract 659: A national analysis of the impact of opioid use disorder on clinical outcomes in hospitalized patients with urothelial carcinoma.**  
First Author: Kristy Rose Bono, MD, MS
- Board C10 Abstract 660: Addressing barriers to adopting first-line standards of care in la/mUC: A community practice-informed initiative.**  
First Author: Kia Jones
- Board C11 Abstract 661: Consensus guidance on early identification and management of peripheral neuropathy in patients with UC receiving enfortumab vedotin: A Delphi study.**  
First Author: Alexandra Drakaki, MD, PhD
- Board C12 Abstract 662: Structured step-based prehabilitation before radical cystectomy and its impact on postoperative recovery and perioperative burden: Interim analysis of the PRACTICE randomized trial (NCT06806059).**  
First Author: Yannic Volz, MD
- Board C14 Abstract 664: Implementing evidence-based first-line therapy for metastatic urothelial carcinoma: A quality improvement initiative in community oncology.**  
First Author: Daniel P. Petrylak, MD
- Board C15 Abstract 665: Characteristics, treatment (tx) patterns and outcomes in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC): A retrospective cohort study in England.**  
First Author: Robert Stevenson
- Board C16 Abstract 666: Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) and frailty or comorbidities.**  
First Author: Enrique Grande, MD, PhD
- Board C17 Abstract 667: Relevance of fresh frozen sections (FFS) for carcinoma in situ (CIS) detection in radical cystectomy for bladder cancer.**  
First Author: David Pfister
- Board C18 Abstract 668: Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.**  
First Author: Elise Y. Cai, MD, PhD
- Board C19 Abstract 669: A real-world US community-based evaluation of recurrence among non-muscle-invasive bladder cancer patients treated with bacillus Calmette-Guérin.**  
First Author: Aram Babcock, PhD, PharmD, MS, MBA
- Board C20 Abstract 670: Impact of neoadjuvant chemotherapy on outcomes of bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.**  
First Author: Yeon Joo Kim, MD, PhD

- Board C21 Abstract 671: Description and management strategies of prespecified treatment emergent adverse events (TEAEs) amongst patients (pts) treated with 1L enfortumab vedotin (EV) + pembrolizumab (P) for la/mUC in a real-world setting.**  
First Author: David Michael Gill, MD
- Board C22 Abstract 672: Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment.**  
First Author: Khilna Patel, PharmD
- Board C24 Abstract 674: Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the JAVEMACS chart review study.**  
First Author: Takashi Kobayashi, MD, PhD
- Board C25 Abstract 675: Survival outcomes in metastatic bladder cancer patients in the United States.**  
First Author: Pedro C. Barata, MD, MSc, FACP
- Board C26 Abstract 676: Treatment patterns and outcomes with second line (2L) therapies in patients (pts) with advanced urothelial carcinoma (aUC) previously treated with first line (1L) enfortumab vedotin (EV) with pembrolizumab (pembro).**  
First Author: Georges Gebrael, MD
- Board D1 Abstract 677: From bladder to upper urinary tract: Unveiling the epidemiological dynamics of urothelial carcinoma.**  
First Author: Gan Du, MMM
- Board D2 Abstract 678: Long-term effectiveness and safety of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC): Updated systematic literature review (SLR) and meta-analysis (MA).**  
First Author: Philippe Barthelemy
- Board D3 Abstract 679: Clinical burden of recurrence among older adults with muscle invasive bladder cancer undergoing tri-modal therapy in the real world: A SEER-Medicare, population-level study.**  
First Author: Ronac Mamtani, MD, MSCE
- Board D4 Abstract 680: Real-world (rw) safety of first-line (1L) systemic regimens for locally advanced or metastatic urothelial cancer (la/mUC): Updated results from the ELEVATE UC-I study.**  
First Author: Amanda Nizam, MD
- Board D5 Abstract 681: FGFR-altered metastatic urothelial carcinoma in the real-world setting: Insight from the multicenter, prospective, non-interventional Italian registry of advanced/metastatic urothelial carcinoma (SATURNO)—A FICOG and Meet-URO study.**  
First Author: Marco Stellato, MD
- Board D6 Abstract 682: Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with advanced urothelial cancer.**  
First Author: Emily Nash Smyth
- Board D7 Abstract 683: Early relative dose intensity to predict survival outcomes in patients treated with enfortumab vedotin for metastatic urothelial carcinoma.**  
First Author: Yuki Endo, MD, PhD
- Board D8 Abstract 684: Neoadjuvant chemotherapy of node-positive M0 urothelial bladder cancer.**  
First Author: Mateusz Malik
- Board D9 Abstract 685: Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedotin (EV) plus pembrolizumab (P).**  
First Author: Nataliya Mar, MD
- Board D10 Abstract 686: Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.**  
First Author: Antonio Cigliola, MD
- Board D11 Abstract 687: End-of-life treatment patterns in patients with advanced urothelial carcinoma.**  
First Author: Diya Garg, BS
- Board D12 Abstract 688: Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).**  
First Author: Mamta Parikh, MD, MS
- Board D13 Abstract 689: Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.**  
First Author: Lucas Antonio Viti-Guzman, BS
- Board D14 Abstract 690: Real-world data on patients' characteristics guiding physicians' choice of first-line treatment for advanced urothelial carcinoma: Is there still a place for platinum-based chemotherapy?**  
First Author: Philippe Barthelemy
- Board D15 Abstract 691: Disitamab vedotin plus PD-1 inhibitors as neoadjuvant therapy for cisplatin-ineligible muscle-invasive bladder cancer: A real-world retrospective study.**  
First Author: Xinjia Ding, PhD
- Board D16 Abstract 692: Real-world use and effectiveness of first-line enfortumab vedotin (EV) with pembrolizumab (P) in patients with advanced urothelial carcinoma (aUC).**  
First Author: Zeynep Irem Ozay, MD
- Board D17 Abstract 693: Real-world endpoints as surrogates for overall survival in metastatic bladder cancer.**  
First Author: Marc Machaalani, MD
- Board D18 Abstract 694: Real-world survival outcomes with single-agent erdafitinib (Erda) in patients (pts) with advanced urothelial carcinoma (aUC) based on line (L) of therapy and prior enfortumab vedotin (EV) treatment (Rx).**  
First Author: Zeynep Irem Ozay, MD

- Board D19 Abstract 695: Prognosis of patients (pts) with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma (la/mUC).**  
First Author: Dimitra Rafailia Bakaloudi, MD, MS, MPA
- Board D20 Abstract 696: Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.**  
First Author: Jeffrey Zhong
- Board D21 Abstract 697: Impact of neoadjuvant chemotherapy on perioperative outcomes following nephroureterectomy.**  
First Author: Rishabh Simhal, MD
- Board D22 Abstract 698: Machine learning-based phenotyping and trial emulation to identify checkpoint inhibitor responders in advanced urothelial cancer.**  
First Author: Xavier Orcutt, MD
- Board D23 Abstract 699: Frequency and determinants of reproductive organ involvement in female patients undergoing radical cystectomy for bladder cancer.**  
First Author: Mazyar Zahir, MD
- Board D24 Abstract 700: Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.**  
First Author: Jorge Esteban Villarrubia, MD
- Board D25 Abstract 701: Predictive value of microsatellite instability/mismatch repair deficiency phenotype in upper tract urothelial carcinoma: A systematic review and meta-analysis.**  
First Author: Yige Bao, MD, PhD
- Board D26 Abstract 702: Oncological outcomes and HER2 expression of urothelial carcinoma with squamous differentiation: A retrospective study.**  
First Author: Xin Wang, MA
- Board E1 Abstract 703: Circulating tumor DNA kinetics as a biomarker of response to enfortumab-pembrolizumab in advanced urothelial carcinoma.**  
First Author: Muhammad Abdullah Humayun, MD, MBBS
- Board E2 Abstract 704: Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).**  
First Author: Tanya Jindal, BS, BA
- Board E3 Abstract 705: Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**  
First Author: Cindy Y. Jiang, MD
- Board E4 Abstract 706: Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network.**  
First Author: Syed Mujtaba Ali Naqvi, MD
- Board E5 Abstract 707: Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.**  
First Author: Dhaval Shah, MD, FACP, MBA
- Board E6 Abstract 708: Front-line (1L) treatment and recurrence patterns among patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT).**  
First Author: Michael Fabrizio, MD
- Board E7 Abstract 709: Quality of care (QoC) measures among patients with recurrent, papillary-only bacillus Calmette-Guérin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC).**  
First Author: Ali Raza Khaki, MD
- Board E8 Abstract 710: Bridging trial and practice: Real-world data of adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.**  
First Author: Takuma Narita, MD
- Board E10 Abstract 712: Real world outcomes comparing the use of GLP-1 agonists in patients with bladder cancer and comorbid obesity: A propensity score matched analysis from the Global Federated Health Research Network.**  
First Author: Arshi Syal, MD
- Board E11 Abstract 713: OncoEducate: A pilot study of generative AI to support patient education in GU cancer care.**  
First Author: Henry Kazunaru Litt, MD
- Board E12 Abstract 714: Integrating pharmacists into uro-oncology care: Evaluation of patient satisfaction and well-being.**  
First Author: Judith Fischer
- Board E13 Abstract 715: Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.**  
First Author: Ruchika Talwar, MD
- Board E14 Abstract 716: Incidence of immune-related adverse events (irAEs) and treatment discontinuation rates (TDR) in the adjuvant and metastatic setting in patients with urological malignancies: A systemic review and meta-analysis.**  
First Author: Laia Fernandez-Mañás, MEd
- Board E15 Abstract 717: Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotin-pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC).**  
First Author: Zachariah Thomas, MBBS
- Board E16 Abstract 718: Acute and chronic GU/GI toxicity after conventional versus hypofractionated radiotherapy (HFRT) with concurrent chemotherapy for muscle-invasive bladder cancer: A multi-institutional analysis by CURE-BC - Consortium for Urothelial Radiation Excellence – Bladder Cancer.**  
First Author: Adeel Riaz, MD, MPhil

- Board E17** **Abstract 719: Clinical outcomes of metastatic urothelial carcinoma patients discontinuing enfortumab vedotin due to toxicity and/or clinical response.**  
First Author: Joy Li, MD
- Board E18** **Abstract 720: Evaluation of quality of life endpoint planning and reporting in phase III genitourinary oncology randomized controlled trials.**  
First Author: Shreyas Kalantri, MD
- Board E19** **Abstract LBA721: Wearable device substudy of DISCUS: A randomised study comparing 3 vs 6 cycles of chemotherapy and sequenced avelumab in urothelial cancer.**  
First Author: Francesca Jackson-Spence, MBChB
- Board E20** **Abstract 722: Implementation of patient reported outcomes as nonmuscle-invasive bladder cancer clinical trial endpoints.**  
First Author: Spencer Bell
- Board E21** **Abstract 723: Preoperative muscle quantity to predict acute kidney injury after radical cystectomy: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board E22** **Abstract 724: Characterizing frailty and its drivers in bladder cancer using machine learning-derived vulnerability and resource phenotypes.**  
First Author: Hilmi Al-Shakshir
- Board E23** **Abstract 725: Acute kidney injury to predict cardiovascular outcomes following radical cystectomy: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board E24** **Abstract 726: Aligning goals of care at the time of treatment planning with the ABC123 framework: A pilot study.**  
First Author: Ryan Stanford Hilton, MD
- Board E25** **Abstract 727: Longitudinal assessment of patient-reported quality of life and mental health during active surveillance for low-grade NMIBC.**  
First Author: Marco Paciotti
- Board E26** **Abstract 728: Does urinary diversion type influence long-term renal outcomes after radical cystectomy? A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board F1** **Abstract 729: Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoring—A systematic review and meta-analysis.**  
First Author: Fernando Blank, MD
- Board F2** **Abstract 730: Comparative treatment burden of BCG versus sequential gemcitabine and docetaxel for non-muscle-invasive bladder cancer: A time toxicity analysis.**  
First Author: Melinda Fu, MD
- Board F3** **Abstract 731: Effects of steroid pretreatment on adverse events and overall survival during enfortumab vedotin in urothelial carcinoma.**  
First Author: Shingo Hatakeyama, MD
- Board F4** **Abstract 732: Adjuvant vs switch-maintenance checkpoint inhibition in urothelial carcinoma: A systematic review and meta-analysis of randomized trials through July 2025.**  
First Author: Farzeen Fatma Syed, MD, MBBS
- Board F5** **Abstract 733: Response to primary chemoablation with UGN-102 in different EOTRC risk groups.**  
First Author: William Huang, MD
- Board F6** **Abstract 734: Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).**  
First Author: Kyung Hae Jung, MD, PhD
- Board F7** **Abstract 735: Impact of FGFR3 alterations on first-line platinum based chemotherapy in patients with metastatic or locally advanced urothelial carcinoma: The retrospective IFUCA study.**  
First Author: Thibaut Reverdy
- Board F8** **Abstract 736: Enfortumab vedotin (EV) related cutaneous toxicity to predict metabolic response on fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in advanced urothelial carcinoma (aUC): A single-center experience.**  
First Author: Raffaele Ratta
- Board F10** **Abstract 738: Comparative outcomes of chemoradiotherapy regimens in muscle-invasive bladder cancer: A retrospective cohort study.**  
First Author: Bharath Gangadhar, MD, DM
- Board F11** **Abstract 739: Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.**  
First Author: Jeannie Hoffman-Censits, MD
- Board F12** **Abstract 740: Clinical outcomes in patients with locally advanced or metastatic urothelial cancer (la/mUC) in France treated with avelumab first-line maintenance (1LM): A real-world observational study using the French National Healthcare Database (Système National des Données de Santé [SNDS]).**  
First Author: Nadine Houede, MD
- Board F13** **Abstract 741: Cystectomy-free survival following cretostimogene grenadenorepvec in high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ: Results from the phase 3 BOND-003 trial (Cohort C).**  
First Author: Gary D. Steinberg, MD
- Board F14** **Abstract 742: Clinical outcomes of neoadjuvant chemotherapy-guided bladder preservation in muscle-invasive bladder cancer: Long-term results of a phase II trial.**  
First Author: Gan Du, MMM
- Board F15** **Abstract 743: ADVANCED-2: Interim efficacy and safety data in BCG-unresponsive participants with high-grade non-muscle invasive bladder cancer.**  
First Author: Raj Satkunasivam, MD, MS

- Board F16** Abstract 744: Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab (Pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from phase 2 2870-002/SKB264-II-06 study.  
First Author: Xiaojie Bian
- Board F17** Abstract 745: Outcomes in participants (pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy (RC) after pembrolizumab (pembro): KEYNOTE-057 cohort A post hoc analysis.  
First Author: Edward M. Uchio, MD
- Board F18** Abstract 746: Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV+P): Exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).  
First Author: Shilpa Gupta, MD
- Board F19** Abstract 747: Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.  
First Author: Guillermo de Velasco, MD, PhD
- Board F20** Abstract 748: Neoadjuvant (Neoadj) gemcitabine intravesical system (Gem-iDRS) plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for/refusing neoadj cisplatin-based chemotherapy (NAC): Updated perioperative outcomes from SunRISe-4.  
First Author: Sarah P. Psutka, MD, MS
- Board G1** Abstract 749: ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients (pts) with high grade (HG) upper tract urothelial carcinoma (UTUC) ineligible for cisplatin-based chemotherapy.  
First Author: Jeannie Hoffman-Censits, MD
- Board G2** Abstract 750: A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.  
First Author: Raj Satkunasivam, MD, MS
- Board G3** Abstract 751: A provocative analysis of first-line strategies in advanced urothelial carcinoma: Reconstructed individual patient data comparisons of EV–pembrolizumab, avelumab maintenance, and nivolumab–cisplatin–gemcitabine from their pivotal phase 3 trials.  
First Author: Andrea Malgeri, MD
- Board G4** Abstract 752: Treatment of recurrent non-muscle invasive bladder cancer with UGN-301 (zalifrelimab) alone and in combination: A phase 1 dose escalation study.  
First Author: Karim Chamie, MD
- Board G6** Abstract 754: Clinical outcomes of pembrolizumab and enfortumab vedotin in variant histology urothelial carcinoma.  
First Author: Tareq Salous, MBBS
- Board G7** Abstract 755: Topline results from BOND-003 cohort P: A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.  
First Author: Siamak Daneshmand, MD
- Board G8** Abstract 756: First results from CORE-008 cohort A: Phase 2 study of intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naïve non-muscle invasive bladder cancer.  
First Author: Gary D. Steinberg, MD
- Board G9** Abstract 757: Clinical outcomes with immune checkpoint inhibitor and/or enfortumab vedotin in patients with MTAP-deleted metastatic urothelial carcinoma.  
First Author: Claire Y. Lin, BS
- Board G10** Abstract 758: A multicenter phase II study of first-line modified FOLFIRINOX in patients with advanced urachal cancer (ULTIMA; KCSG GU20-03).  
First Author: Inkeun Park, MD, PhD
- Board G11** Abstract 759: Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.  
First Author: Steven Neema Seyedin, MD
- Board G12** Abstract 760: The impact of neoadjuvant chemotherapy relative dose intensity on pathological complete response and survival in muscle-invasive urothelial cancer: A multicentric retrospective study.  
First Author: Giuseppe Neola, MD
- Board G14** Abstract 762: Intravesical T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in BCG-naïve high-risk NMIBC: A phase IIa trial.  
First Author: Dingwei Ye
- Board G16** Abstract 764: Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).  
First Author: Dingwei Ye
- Board G17** Abstract 765: Neoadjuvant tislelizumab in combination with disitamab vedotin (RC48) followed by distal ureterectomy for patients with HER-2 expressing lower segment ureteral carcinoma (LSUC): A single-arm, phase II, single-center study.  
First Author: Houyuan Chen
- Board G18** Abstract 766: Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results.  
First Author: Xinan Sheng, MD
- Board G19** Abstract 767: Association of renal function in non-hydronephrotic patients receiving PD-1 ICIs for bladder cancer with treatment response.  
First Author: Chong Shen

- Board G20** **Abstract 768: Fixed low-dose nab-paclitaxel with tislelizumab in non-metastatic bladder cancer: A post-hoc analysis of dose expose in TRUCE-01 and TRUCE-02 trials.**  
First Author: Hailong Hu, MD, PhD
- Board H1** **Abstract 769: Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.**  
First Author: Andrea Necchi, MD
- Board H2** **Abstract 770: ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following prior therapies for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).**  
First Author: Rohit K. Jain, MD, MPH
- Board H3** **Abstract 771: Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial.**  
First Author: Ho Kyung Seo, MD, PhD
- Board H4** **Abstract 772: Efficacy and safety of disitamab vedotin combined with intravesical electromotive mitomycin-C in patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A phase II study.**  
First Author: Xuebing Han
- Board H5** **Abstract 773: Safety and efficacy of platinum-based neoadjuvant chemotherapy with gemcitabine at 800 mg/m<sup>2</sup> vs. 1000 mg/m<sup>2</sup> in muscle-invasive bladder cancer: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board H6** **Abstract 774: The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.**  
First Author: Yige Bao, MD, PhD
- Board H7** **Abstract 775: Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Final results from a phase II study.**  
First Author: Xingang Bi, MD, PhD
- Board H8** **Abstract 776: Interim safety and tolerability of TARA-002 in patients with BCG-naïve and unresponsive high-grade non-muscle invasive bladder cancer in ADVANCED-2.**  
First Author: Timothy Clinton, MD
- Board H9** **Abstract 777: Effect of maximal transurethral resection before neoadjuvant chemotherapy on pathological response and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board H10** **Abstract 778: Real-world comparative outcomes of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in metastatic urothelial carcinoma.**  
First Author: Baqir Jafry, MD
- Board H11** **Abstract 779: Perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): An IPD-based comparative analysis of KEYNOTE-905/EV-303 and PURE-01.**  
First Author: Brigida Maiorano
- Board H12** **Abstract 780: Effect of HER2 IHC on enfortumab vedotin (EV) or EV+pembrolizumab (EVP) benefit in metastatic urothelial carcinoma.**  
First Author: Jungmin Jo, MD
- Board H13** **Abstract 781: Effect of censorship in the interpretation of outcomes of the enfortumab vedotin plus pembrolizumab EV-302 phase 3 randomized clinical trial.**  
First Author: Aaron Zhang
- Board H14** **Abstract 782: Preliminary results from phase II enfortumab vedotin plus toripalimab compared to gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).**  
First Author: Li Zhou, PhD
- Board H15** **Abstract 783: Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer.**  
First Author: Kaiwen Li, MD
- Board H16** **Abstract 784: Drug-releasing intravesical floating technology (DRIFT) for administration of sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.**  
First Author: Melinda Fu, MD
- Board H17** **Abstract 785: Optimizing docetaxel bladder penetration following gemcitabine pretreatment: An analysis of concentration and timing protocols.**  
First Author: Melinda Fu, MD
- Board H18** **Abstract 786: Transcriptomic deep learning approach for predicting chemotherapy response to cisplatin and gemcitabine in urothelial carcinoma.**  
First Author: Kwonoh Park, MD, PhD
- Board H19** **Abstract 787: EGFR, HER2 alterations in advanced urothelial carcinoma (aUC): A retrospective analysis on survival outcomes.**  
First Author: Pearl Subramanian, MD
- Board H20** **Abstract 788: Effect of programmed cell death protein ligand 1 nuclear translocation mediated by Enolase on urothelial carcinoma immune evasion.**  
First Author: Honggang Ying, PhD
- Board H21** **Abstract 789: Genomic landscape of metastatic urothelial cancer in a multicenter Argentine cohort.**  
First Author: Federico Cayol, MD, MSc
- Board H22** **Abstract 790: Investigation of the natural killer (NK) cell axis in decoy-resistant IL18 treatment in bladder cancer (BCa).**  
First Author: Zaineb Hassouneh, MS

- Board H23** **Abstract 791: Validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in muscle invasive bladder cancer.**  
First Author: Yair Lotan, MD
- Board H24** **Abstract 792: Inhibiting  $\alpha$ 2,6-sialylation and its association with nectin-4 stability and macropinocytic uptake in bladder cancer.**  
First Author: Bisheng Cheng
- Board H25** **Abstract 793: Early peripheral blood neutrophil/lymphocyte ratio (NLR) dynamics to predict primary refractory disease in metastatic urothelial carcinoma (mUC) patients receiving PD1/L1 inhibitors.**  
First Author: Bakr Alhayek, MD
- Board H26** **Abstract 794: Impact of HER2 expression and *ERBB2* alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.**  
First Author: Kevin R. Reyes, MD
- Board J1** **Abstract 795: Comprehensive plasma metabolomic profiling of metastatic urothelial carcinoma (mUC) pre- and post-immune checkpoint inhibitor (ICI) or platinum-based chemotherapy (PBC).**  
First Author: Susmita Potti, MBBS
- Board J2** **Abstract 796: Association of HER2 and NECTIN4 expression with clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).**  
First Author: Kevin R. Reyes, MD
- Board J3** **Abstract 797: Integrating genomic profiling and circulating tumor DNA monitoring to optimize surveillance strategies in muscle-invasive bladder cancer.**  
First Author: Can Aydogdu, MD
- Board J4** **Abstract 798: Clinical utility of circulating tumor DNA profiling in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.**  
First Author: Yoshiyuki Yamamoto, MD, PhD
- Board J5** **Abstract 799: *ERBB3*-altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.**  
First Author: Steven M. Blinka, MD, PhD
- Board J6** **Abstract 800: Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).**  
First Author: Tanya Jindal, BS, BA
- Board J7** **Abstract 801: Membranous and cytoplasmic Nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.**  
First Author: Michal Sternschuss, MD
- Board J8** **Abstract 802: Proliferation- and immune-informed fusion of multiscale image features for bladder cancer prognosis.**  
First Author: Himanshu Maurya
- Board J9** **Abstract 803: HER2 expression and genomic alterations in plasmacytoid urothelial carcinoma: Results from a large real-world institutional cohort.**  
First Author: Can Aydogdu, MD
- Board J10** **Abstract 804: Low-coverage whole-genome sequencing of urinary tumor DNA to characterize genomic correlates of lymphovascular invasion in bladder cancer.**  
First Author: Zihan Xue, MD
- Board J11** **Abstract 805: Prognostic and predictive impact of HER-2 expression in metastatic urothelial carcinoma: Results from the single-centre BLADDER study.**  
First Author: Elisa Erbetta, MD
- Board J12** **Abstract 806: Sasanlimab plus bacillus Calmette-Guérin in BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): Exploratory biomarker analysis of the phase 3 CREST trial.**  
First Author: Matthew D. Galsky, MD, FASCO
- Board J13** **Abstract 807: Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder.**  
First Author: Saumil Datar, MD
- Board J14** **Abstract 808: Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: A potential genetic implication for risk stratification and target therapy.**  
First Author: Rodolfo Hurle, MD
- Board J15** **Abstract 809: ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.**  
First Author: Andrew J. Murtha, BSc
- Board J16** **Abstract 810: Ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based ctDNA assay in resectable urothelial cancer in the MONSTAR-SCREEN-3 project.**  
First Author: Shigehiro Tsukahara
- Board J17** **Abstract 811: Effect of tumor methionine metabolism via MAT2A on CD8<sup>+</sup> T-cell exhaustion through SAM-CHOP axis in bladder cancer.**  
First Author: Zhe Zhang, MD, PhD
- Board J18** **Abstract 812: Metaproteomics based subtypes in muscle invasive bladder carcinoma and association with survival.**  
First Author: Alvaro Pinto, MD, PhD
- Board J19** **Abstract 813: Mechanistic insights into bacillus Calmette-Guérin (BCG) sensitivity in non-muscle invasive bladder cancer (NMIBC) with ERCC2 alterations.**  
First Author: Vincent D'Andrea, MD
- Board J20** **Abstract 814: Impact of tumor mutational burden on clinical outcomes in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy.**  
First Author: Earle F. Burgess, MD, MD

- Board J21** **Abstract 815: Integrating circulating tumor DNA (ctDNA) and *TP53* alteration variant allele frequency (VAF) to predict outcomes in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).**  
First Author: Abby Grier, BA
- Board J22** **Abstract 816: Effect of loss of KDM6A-mediated genomic instability and metabolic reprogramming on response to therapeutic perturbations in bladder cancer.**  
First Author: Sangeeta Goswami, MD, PhD
- Board J23** **Abstract 817: Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: A subgroup analysis of the phase II POLARIS-03 trial.**  
First Author: Jinchang Wei, MD
- Board J24** **Abstract 818: Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin ± pembrolizumab: A single-cell spatial transcriptomic analysis.**  
First Author: Brendan Raizenne, MD
- Board J25** **Abstract 819: Detecting *MTAP* loss in liquid biopsies from patients (pts) with clinically advanced urothelial bladder cancer (CAUBC).**  
First Author: Chiara Mercinelli, MD
- Board J26** **Abstract 820: Prospective, blinded validation of a urinary cfDNA methylation assay in bladder cancer.**  
First Author: Yonaton Zerbiv, MD, MSc
- Board K1** **Abstract 821: ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.**  
First Author: Edwin Lin, PhD, MA
- Board K2** **Abstract 822: Clinical utility of a urinary DNA methylation biomarker test in the diagnosis and surveillance of upper tract urothelial carcinoma: Results from a prospective trial.**  
First Author: Alireza Ghoreifi, MD
- Board K3** **Abstract 823: Immune senescence and antigen presentation defects in BCG-unresponsive bladder cancer.**  
First Author: Jee Soo Park, MD, PhD
- Board K4** **Abstract 824: Multidimensional profiling of clinical trial cohorts and the characterization of radiotherapy/immunotherapy response biology in localised and metastatic muscle-invasive bladder cancer.**  
First Author: Rose Foster, PhD
- Board K5** **Abstract 825: Toward noninvasive genomic profiling in muscle-invasive bladder cancer using quantitative CT texture analysis.**  
First Author: Aidan Boyne
- Board K6** **Abstract 826: Circulating tumor cell detection and prognostic relevance in patients with metastatic genitourinary cancers.**  
First Author: Miles Hsu, MD
- Board K7** **Abstract 827: HER2 and nectin-4 IHC expression and clinical outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.**  
First Author: David H. Aggen, MD, PhD
- Board K8** **Abstract 828: Next-generation sequencing of bladder and upper tract micropapillary variant urothelial carcinoma patients and associated clinical outcomes.**  
First Author: Sean Thomas McSweeney, MD
- Board K9** **Abstract 829: Homologous recombination repair gene alterations and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.**  
First Author: Giuseppe Salfi, MD
- Board K10** **Abstract 830: Detecting *FGFR3* genomic alterations in liquid biopsies from patients with clinically advanced urothelial bladder cancer.**  
First Author: Michael Basin, MD
- Board K11** **Abstract 831: Association of ctDNA status with upstaging, pathologic outcomes, and genomic alterations in high-risk NMIBC.**  
First Author: Can Aydogdu, MD
- Board K12** **Abstract 832: Biomarker analysis of neoadjuvant atezolizumab in upper-tract urothelial carcinoma: Results from the ABACUS-2 trial.**  
First Author: Bernadett Emma Szabados, MD
- Board K13** **Abstract 833: Tumor mutational burden to predict overall survival independent of TP53 status in TCGA bladder cancer cohort.**  
First Author: Canan Dilay Dirican, MD
- Board K14** **Abstract 834: Prognostic utility of tumor mutational burden in older adults (≥75 years) with bladder cancer: A TCGA geriatric oncology analysis.**  
First Author: Canan Dilay Dirican, MD
- Board K15** **Abstract 835: The molecular mechanism of lymph node metastasis driven by B lymphocyte FOXO1 palmitoylation induced by ACSL5 deficiency in bladder cancer cells.**  
First Author: Yifan Sun, MD
- Board K16** **Abstract 836: The overlooked culprit: Tumor size in muscle-invasive bladder cancer.**  
First Author: Mazyar Zahir, MD
- Board K17** **Abstract 837: Circulating tumor DNA analysis from the prospective pT0 study of systematic endoscopic evaluation in patients undergoing radical cystectomy for bladder cancer.**  
First Author: Matthew R. Zibelman, MD
- Board K18** **Abstract 838: Duplex-Seq derived urinary cell-free DNA of Lynch syndrome patients with upper tract urothelial carcinoma.**  
First Author: Alex Zhu, DO
- Board K19** **Abstract 839: Ferroptosis suppression and its association with chemoradiotherapy resistance in muscle-invasive bladder cancer.**  
First Author: Takuya Tsujino, MD, PhD

- Board K20** **Abstract 840: Comprehensive multi-layered omics analysis of the UBC landscape for precision medicine and its clinical implications: From deciphering distinct molecular heterogeneity to guiding treatment decision-making and developing tailored therapeutic strategies.**  
First Author: Ho Kyung Seo, MD, PhD
- Board K21** **Abstract 841: A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients.**  
First Author: Joep Jacobus de Jong, MD
- Board K22** **Abstract 842: A binary dual-stain immunohistochemistry classifier to predict pathologic downstaging after neoadjuvant chemotherapy in muscle-invasive bladder cancer.**  
First Author: Jungmin Jo, MD
- Board K23** **Abstract 843: Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.**  
First Author: Joep Jacobus de Jong, MD
- Board K24** **Abstract 844: Liquid biopsy-based detection of MTAP gene loss in non-muscle invasive bladder cancer.**  
First Author: Tiantian Zheng
- Board K25** **Abstract 845: Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.**  
First Author: Joep Jacobus de Jong, MD
- Board K26** **Abstract 846: Blood- and urine-based ctDNA profiling and monitoring in bladder carcinoma in situ.**  
First Author: Ruiyun Zhang
- Board L1** **Abstract 847: Blood and urine liquid biopsy for molecular monitoring in HER2-positive muscle-invasive bladder cancer under bladder-preserving therapy.**  
First Author: Jiani Deng
- Board L2** **Abstract 848: Real-world urinary detection of FGFR alterations to guide FGFR inhibitor therapy in bladder cancer.**  
First Author: Jingyu Zang
- Board L3** **Abstract 849: Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study).**  
First Author: Ruiyun Zhang
- Board L4** **Abstract 850: Development of a non-muscle invasive bladder cancer (NMIBC) genomic score (NGS) to predict early BCG failure.**  
First Author: Mark Farha
- Board L5** **Abstract 851: Examining the impact of TGF- $\beta$  activity on fibroblast infiltration and immune exclusion in MIBC.**  
First Author: Shilpa Gupta, MD
- Board L6** **Abstract 852: Hemoglobin, albumin, lymphocyte, and platelet (HALP) score as a prognostic indicator in patients with bladder cancer undergoing radical cystectomy.**  
First Author: J. Everett Knudsen
- Board L7** **Abstract 853: Homologous recombination deficiency signature (HRDsig) in adenocarcinoma of the bladder (ACB): Implications for PARP inhibitor (PARPi) treatment.**  
First Author: Antonio Cigliola, MD
- Board L8** **Abstract 854: Membranous Nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma.**  
First Author: Niklas Klümper, MD
- Board L9** **Abstract 855: Bladder cancer innervation: Does it affect prognosis?**  
First Author: Pavel Babal, MD, PhD
- Board L10** **Abstract 856: Multi-omic remodeling of urine-exposed ileal mucosa after ileocystoplasty.**  
First Author: Peixin Li
- Board L11** **Abstract 857: Preoperative CT radiomics–deep learning signature for lymphovascular invasion in bladder cancer: External validation and clinical utility.**  
First Author: Shijie Zhang
- Board L12** **Abstract 858: Genomic heterogeneity in urothelial carcinoma with trophoblastic differentiation: Real world data.**  
First Author: Gabriela Diaz
- Board L13** **Abstract 859: Prognostic significance of the preoperative De Ritis ratio and its association with sarcopenia in muscle-invasive bladder cancer: A multicenter retrospective study.**  
First Author: Naoki Fujita, MD, PhD
- Board L14** **Abstract 860: Circulating tumor DNA dynamics as a predictive biomarker of response and survival in metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab.**  
First Author: Lingbin Meng, MD, PhD
- Board L15** **Abstract 861: Clinical, radiographic, and genomic predictors of response to neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma.**  
First Author: Viranda Jayalath, MD, MSc
- Board L16** **Abstract 862: Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.**  
First Author: Salvador Jaime-Casas, MD
- Board L17** **Abstract 863: Autoantibody (AAb) profiling in metastatic cisplatin-ineligible metastatic urothelial carcinoma (mUC) treated with ipilimumab (IPI), nivolumab (NIVO), and sacituzumab govitecan (SG).**  
First Author: Rohit K. Jain, MD, MPH
- Board L18** **Abstract 864: Histopathologic and spatial transcriptomic analyses of en bloc resections of de novo and recurrent bladder tumors.**  
First Author: Dylan Peterson, MD, MS

- Board L19** **Abstract 865: Association of urothelial carcinoma with squamous differentiation with Nectin-4 expression and outcomes with enfortumab vedotin (EV) treatment.**  
First Author: Jonas Saal
- Board L20** **Abstract 866: Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.**  
First Author: Mehmet Murat Zerey, MD
- Board L21** **Abstract 867: Comparison of clinicopathological features and prognoses of de-novo metastatic male and female bladder cancer patients.**  
First Author: Izzet Dogan, MD
- Board L22** **Abstract 868: Family awareness of genetic risk in affected Caucasian ancestry members with bladder cancer (BC) associated with germline variants in DNA-repair genes (gDRGs).**  
First Author: Giovanni Lughezzani, MD
- Board L23** **Abstract 869: Fostering inclusive language for genitourinary cancer research: A multi-stakeholder co-creation effort.**  
First Author: Alex Filicevas, MA
- Board L24** **Abstract 870: Artificial intelligence in the diagnosis and prognosis of upper tract urothelial carcinoma: A comprehensive review of current evidence, methodological standards, and future directions.**  
First Author: Rui d'Avila
- Board L25** **Abstract 871: Healthcare resource utilization (HCRU) and costs among US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with first-line (1L) treatment regimens: Results from the ELEVATE UC-I study.**  
First Author: Amanda Nizam, MD
- Board L26** **Abstract 872: Impact of positive ureteral margin on upper tract recurrence after radical cystectomy for bladder cancer.**  
First Author: Mazyar Zahir, MD
- Board M1** **Abstract 873: Inpatient outcomes of bladder cancer: Racial and socioeconomic disparities in a nationally representative sample (2020-2022).**  
First Author: Hareem Tahir, MD, MBBS
- Board M2** **Abstract 874: Does time to recurrence after radical cystectomy for bladder cancer impact subsequent survival?**  
First Author: Mazyar Zahir, MD
- Board M3** **Abstract 875: Effect of epidural analgesia vs. combined intravenous patient-controlled analgesia and transversus abdominis plane block on postoperative outcomes after radical cystectomy.**  
First Author: Naoki Fujita, MD, PhD
- Board M4** **Abstract 876: A novel large language model framework for automated extraction of pathology data in radical cystectomy.**  
First Author: Jacob Michael Knorr, MD
- Board M5** **Abstract 877: Antibody-drug conjugates in genitourinary malignancies: The clinical trial landscape and emerging efficacy benchmarks.**  
First Author: Sanjay Khanna, MBBS
- Board M6** **Abstract 878: Quantifying the value of tumor response and survival: Perceived monetary loss in anticancer therapy.**  
First Author: Takuma Narita, MD

11:30 AM-12:45 PM and 4:45 PM-5:45 PM  
**Trials in Progress Poster Session B: Urothelial Carcinoma**  
Level 1, West Hall

**Posters by Topic**

**Urothelial Carcinoma**

- Diagnostics and Imaging: M7
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: M8, M9
- Therapeutics: M10-M26, N1-N11
- Translational Research, Tumor Biology, Biomarkers, and Pathology: N12-N25
- Other: N26

**Board M7** **Abstract TPS879: Bladder cancer (BC) screening in un-affected Caucasian ancestry family members of patients who tested positive for germline homologous recombination repair (gHRR) and mismatch repair (gMMR) variants.**  
First Author: Massimo Lazzeri, MD, DrPH

**Board M8** **Abstract TPS880: A phase III randomised control clinical trial of radiotherapy with radiosensitisation versus intravesical bacillus Calmette-Guerin therapy for high-risk non-muscle invasive bladder cancer: TRAIN.**  
First Author: Ananya Choudhury, PhD, MA, MRCP, FRCR

**Board M9** **Abstract TPS881: The EMPOWER trial: Evaluating a home-based physical activity program (PAP) with the ExerciseRx digital platform vs. health education (HE) in people with non-muscle invasive bladder cancer (NMIBC).**  
First Author: Sarah P. Psutka, MD, MS

**Board M10** **Abstract TPS882: Intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk non-muscle-invasive bladder cancer: The phase 2 INTerpath-011 study.**  
First Author: Roger Li, MD

**Board M11** **Abstract TPS883: IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.**  
First Author: Thomas Powles, MD, PhD, FCRP

**Board M12** **Abstract TPS884: ResQ133A-NMIBC: A phase 1/2 clinical trial of intravesical recombinant mycobacterium bacillus Calmette-Guerin (rBCG) in participants living with non-muscle invasive bladder cancer eligible to receive conventional BCG.**  
First Author: Joshua J. Meeks, MD, PhD

**Board M13** **Abstract TPS885: EV-PRIME: Phase Ib/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer.**  
First Author: Vadim S. Koshkin, MD

**Board M14** **Abstract TPS886: A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).**  
First Author: Gautam Jayram, MD

**Board M15** **Abstract TPS887: Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.**  
First Author: Yiming Su, MD

**Board M16** **Abstract TPS888: A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk non-muscle invasive bladder cancer unresponsive to BCG.**  
First Author: Martin Angel, MD

**Board M17** **Abstract TPS889: A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy.**  
First Author: Jason Robert Brown, MD, PhD

**Board M18** **Abstract TPS890: TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab (pembro).**  
First Author: Matthew D. Galsky, MD, FASCO

**Board M19** **Abstract TPS891: HCRN GU22-598: Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder.**  
First Author: Eric James Miller, MD

**Board M20** **Abstract TPS892: CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.**  
First Author: Jabra Zarka, MD

**Board M21** **Abstract TPS893: Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV).**  
First Author: Pooja Ghatalia, MD

**Board M22** **Abstract TPS894: A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.**  
First Author: Sarmad Sadeghi, MD, PhD

**Board M23** **Abstract TPS895: FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.**  
First Author: Melissa A. Reimers, MD, MD

- Board M24** Abstract TPS896: CORE-008 cohort B: Evaluating intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-exposed non-muscle invasive bladder cancer.  
First Author: Trinity Bivalacqua, MD, PhD
- Board M25** Abstract TPS897: Design and implementation of a patient-centric expanded access program with cretostimogene grenadenorepvec in non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.  
First Author: Sarah P. Psutka, MD, MS
- Board M26** Abstract TPS898: Rescuing cancer immunotherapy with plasma exchange in bladder cancer 1 (ReCIPE-B1).  
First Author: Anthony Tabiim
- Board N1** Abstract TPS899: EMPOWER01: A phase II study of zanidatamab combined with bacillus Calmette-Guerin (BCG) in HER2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).  
First Author: Zongren Wang
- Board N2** Abstract TPS900: SASAN-SPARING: A phase 2 trial of sasanlimab maintenance as bladder-sparing option after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.  
First Author: Elena Sevillano, MD
- Board N3** Abstract TPS901: A phase 2 study of gemcitabine plus carboplatin as second-line therapy after prior enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.  
First Author: Gregory Hemenway, MD
- Board N4** Abstract TPS902: [<sup>225</sup>Ac]Ac-AKY-1189, a Nectin-4 targeted radiopharmaceutical, in patients with previously treated locally advanced or metastatic solid tumors: Phase 1b Nectinium-2 study.  
First Author: Timothy A. Yap, MD, PhD
- Board N5** Abstract TPS903: RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a bispecific antibody for the treatment of advanced bladder cancer and other tumors associated with Nectin-4 expression.  
First Author: Benjamin Garmezy, MD
- Board N6** Abstract TPS904: IMGeS study: A prospective, multicentre, phase II trial of sequential intravesical mitomycin-C and gemcitabine therapy in BCG-unresponsive high-risk NMIBC ineligible for or declining radical cystectomy.  
First Author: Ho Kyung Seo, MD, PhD
- Board N7** Abstract TPS905: A phase II study evaluating the efficacy and safety of perioperative enfortumab vedotin plus toripalimab combined with endoscope-based kidney-sparing surgery for patients with high-risk upper tract urothelial carcinoma (WUTSUP-04-EV-JS001).  
First Author: Yige Bao, MD, PhD
- Board N8** Abstract TPS906: LUNAR: Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma—A single-arm, open-label phase 1/2 trial.  
First Author: Seth P. Lerner, MD
- Board N9** Abstract TPS907: Circulating tumor DNA response adapted treatment de-escalation in metastatic urothelial carcinoma (CT-READ).  
First Author: Abdul Qadar, MD
- Board N10** Abstract TPS908: A phase 1/2, first-in-human study of AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), as monotherapy and in combination therapy in patients with locally advanced or metastatic urothelial cancer (UC) or other solid tumors.  
First Author: Benjamin Garmezy, MD
- Board N11** Abstract TPS909: The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).  
First Author: Eugene J. Pietzak, MD
- Board N12** Abstract TPS910: Randomized trial of urinary tumor DNA (utDNA) testing-guided repeat transurethral resection (re-TURBT) in non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB01.  
First Author: Hailong Hu, MD, PhD
- Board N13** Abstract TPS911: Randomized trial of urinary tumor DNA (utDNA) testing-guided cystoscopy in high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB02.  
First Author: Hailong Hu, MD, PhD
- Board N25** Abstract TPS912: CONSOLIDATE: A phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA.  
First Author: Patrick Carriere, MD, PhD
- Board N26** Abstract TPS913: SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).  
First Author: Leslie K. Ballas, MD

7:00 AM-8:10 AM and 11:30 AM-12:45 PM

**Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers**

Level 1, West Hall

**Posters by Topic**

**Adrenal Cancer**

- Therapeutics: A1

**Penile Cancer**

- Health Care Access and Outcomes: A2, A3
- Quality of Care/Quality Improvement: A4
- Real-World Evidence: A5, A6
- Translational Research, Tumor Biology, Biomarkers, and Pathology: A8-A12

**Renal Cell Cancer**

- Diagnostics and Imaging: A13-A17
- Health Care Access and Outcomes: A18-A22
- Quality of Care/Quality Improvement: A23
- Real-World Evidence: A25, A26, B1-B26, C1-C21
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: C22-C26
- Therapeutics: D2-D23
- Translational Research, Tumor Biology, Biomarkers, and Pathology: D24-D26, E1-E26, F1-F17
- Other: F18-F20, G1-G6

**Testicular Cancer**

- Diagnostics and Imaging: G7-G9
- Health Care Access and Outcomes: G10-G14
- Quality of Care/Quality Improvement: G15
- Real-World Evidence: G16-G20, H1-H3
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: H4-H7
- Therapeutics: H8, H9, H10, H11
- Translational Research, Tumor Biology, Biomarkers, and Pathology: H12-H20
- Other: H21

**Urethral Cancer**

- Real-World Evidence: H22

**Board A1 Abstract 1: Comparative outcomes of radiotherapy and interventional therapy for adrenal oligometastases: A multicenter retrospective study.**  
First Author: Yanke Zhang

**Board A2 Abstract 3: Impact of treatment approaches on survival in bulky node-positive penile squamous cell carcinoma: A National Cancer Database analysis.**  
First Author: Atulya Aman Khosla, MD

**Board A3 Abstract 4: Educational representation of genitourinary malignancies in medical student curricula: A cross-sectional review of oncologic education in Caribbean and South American schools.**  
First Author: Amruth Akhil Alluri, BA

**Board A4 Abstract 5: End-of-life care preferences in penile cancer patients: Shifting patterns and disparities over two decades.**  
First Author: Mahnoor Sukaina, MBBS

**Board A5 Abstract 6: Unveiling the rare: p16 expression and real-world management of penile cancer in Bolivia—Insights from a country with high HPV and penile cancer prevalence.**  
First Author: Lucia Richter, MD, OCN

**Board A6 Abstract 7: Real-world outcomes of systemic therapy in penile cancer: A single-center experience from a tertiary referral hospital in Mexico.**  
First Author: Román Alberto Mac-Gregor Hernández, BM

**Board A8 Abstract 9: Single-cell transcriptomic characterization of NECTIN-4 expression in penile squamous cell carcinoma.**  
First Author: Jeffrey S. Johnson, MD

**Board A9 Abstract 10: Multi-hit *PIK3CA* mutations in clinically advanced (CA) penile squamous cell carcinoma (penSCC): A genomic landscape study.**  
First Author: Anupa Rani Mandava, MD, MHA

**Board A10 Abstract 11: *MTAP* loss in penile squamous cell carcinoma (penSCC): A genomic landscape study.**  
First Author: Eyal Kord, MD, MPH

**Board A11 Abstract 12: Spatial and molecular determinants of response in penile squamous cell carcinoma.**  
First Author: Firas Hatoum, MD

**Board A12 Abstract 13: The prognostic role of PD-L1 in penile squamous cell carcinoma: A systematic review and meta-analysis.**  
First Author: Nadine Mahmoud, MD

**Board A13 Abstract 425: Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (MeetUro 31): Preliminary analysis of radiomics features—A Meet-URO and AIRC study (NCT05782400).**  
First Author: Giuseppe Procopio, MD, MEd

**Board A14 Abstract 426: The application of 5.0-Tesla non-enhanced MRI in the preoperative assessment of renal tumors.**  
First Author: Xianda Chen

**Board A15 Abstract 427: External validation of AI age discrepancy as a measure of frailty in kidney tumor patients.**  
First Author: Rikhil Seshadri

**Board A16 Abstract 428: Prediction of socioeconomic disadvantage using AI analysis of CT imaging in kidney cancer patients.**  
First Author: Jacob Michael Knorr, MD

**Board A17 Abstract 429: Predicting clear cell subtype for kidney tumors from cross-sectional imaging using artificial intelligence.**  
First Author: Haya Abusafieh

**Board A18 Abstract 430: Improving access to clinical trial participation among underrepresented kidney cancer patients.**  
First Author: Kimberly Costello, CCRC, BSN, OCN

**Board A19 Abstract 431: Geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the United States (US).**  
First Author: George Zhang

- Board A20** **Abstract 432: Palliative care utilization and hospitalization outcomes among patients with renal cell carcinoma: A 2020-2022 National Inpatient Sample analysis.**  
First Author: Hareem Tahir, MD, MBBS
- Board A21** **Abstract 433: Comparison of outcomes of contemporary immune-check point inhibitors combinations in Black patients versus White patients with metastatic renal cell carcinoma (mRCC).**  
First Author: Kemuel Clarke, BS
- Board A22** **Abstract 434: Trends in renal cell carcinoma mortality associated with tobacco use in U.S. adults aged  $\geq 45$  years, 1999–2023: A population-based CDC WONDER analysis.**  
First Author: Muhammad Zahid Anwar, MBBS
- Board A23** **Abstract 435: Postoperative surveillance in non clear cell renal cancer: Is current practice best practice?**  
First Author: Arighno Das, MD
- Board A25** **Abstract 437: Second-line therapy after ipilimumab and nivolumab in advanced renal cell carcinoma: A multicenter real-world study (GUARDIANS).**  
First Author: Hendrik Dinkel, MD
- Board A26** **Abstract 438: Real-world effectiveness and safety of first-line (1L) avelumab + axitinib (ave + axi) in patients with advanced renal cell carcinoma (aRCC): Final analysis of the prospective AVION study.**  
First Author: Axel Stuart Merseburger, MD, PhD
- Board B1** **Abstract 439: Deferred cytoreductive nephrectomy in patients with advanced RCC treated with first-line nivolumab plus ipilimumab: A propensity score-matched analysis from the RENOIR study (KCSG GU22-13).**  
First Author: Jwa Hoon Kim, MD
- Board B2** **Abstract 440: Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.**  
First Author: Takafumi Minami
- Board B3** **Abstract 441: A multi-institution analysis of outcomes with first-line ipilimumab and nivolumab for 514 patients with metastatic clear cell renal cell carcinoma by number of doses.**  
First Author: Sahil D. Doshi, MD
- Board B4** **Abstract 442: Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L).**  
First Author: Ethan Murdock, BS
- Board B5** **Abstract 443: Patient and physician preferences for treatment in advanced renal cell carcinoma (PEAR): An international, multi-centre discrete choice experiment (DCE).**  
First Author: Alison Yan Zhang, PhD, MMed, MBBS, FRACP
- Board B6** **Abstract 444: Clinical outcomes and tolerability of ipilimumab/nivolumab in older ( $\geq 70$  years) versus younger patients with metastatic clear cell RCC: A multi-institutional analysis of 514 patients.**  
First Author: Antonio Ocejo, MD
- Board B7** **Abstract 445: Serum IgG: A novel biomarker for efficacy and prognosis in metastatic clear cell renal cell carcinoma patients receiving first-line immunotherapy combined with tyrosine kinase inhibitors.**  
First Author: Tian Han, MD
- Board B8** **Abstract 446: Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC.**  
First Author: Martin Zarba, MD, MSc
- Board B10** **Abstract 448: Real-world analysis of renal cell carcinoma with sarcomatoid differentiation treated with first-line immunotherapy combinations: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).**  
First Author: Noelle Thundathil
- Board B11** **Abstract 449: Differential performance of immune-combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma (mRCC) with sarcomatoid features (sRCC) (Meet-URO 33 analysis).**  
First Author: Sara Elena Rebuzzi, MD, PhD
- Board B12** **Abstract 450: Intratumoral mature TLSs to predict response to ICI rechallenge in non-clear cell renal cell carcinoma.**  
First Author: Yanfeng Tang
- Board B13** **Abstract 451: A retrospective evaluation of treatment patterns following cabozantinib treatment for advanced renal cancer: The CABONEXT study.**  
First Author: Simon Nannini, MD
- Board B14** **Abstract 452: Optimal hour of immune checkpoint inhibitors (ICIs) administration in metastatic renal cell carcinoma (mRCC): The “Tic-Tac” study.**  
First Author: Giulia Mammoni
- Board B15** **Abstract 453: Impact of age on outcomes in metastatic non-clear cell renal cell carcinoma (mnccRCC): A real-world TriNetX analysis.**  
First Author: Antonio Cigliola, MD
- Board B16** **Abstract 454: Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study.**  
First Author: Alireza Ghoreifi, MD
- Board B17** **Abstract 455: Associations of DNA damage repair (DDR) pathway class and allelic configuration with survival in metastatic renal cell carcinoma.**  
First Author: Nonna Shakhnazaryan, BS
- Board B18** **Abstract 456: Sarcomatoid versus rhabdoid dedifferentiation and histologic grade-specific outcomes in metastatic clear cell renal cell carcinoma (mccRCC): A multi-institutional analysis of 514 patients.**  
First Author: Nazli Dizman, MD

- Board B19 Abstract 457: Prognostic value of neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal-cell carcinoma treated with immunotherapy.**  
First Author: Patrik Palacka, MD, PhD, MBA, MPH
- Board B20 Abstract 458: Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma.**  
First Author: Eleanor McCarthy, MBChB
- Board B21 Abstract 459: Partial nephrectomy (PN) versus ablative therapies (AT) for T1a clear cell renal cell carcinoma (ccRCC): Analysis of 2,161 patients.**  
First Author: Chang Gon Kim, MD, PhD
- Board B22 Abstract 460: Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data from the Canadian Kidney Cancer Information System (CKCis) database.**  
First Author: Alexandre da Silva Faco Jr, MD
- Board B23 Abstract 461: Real-world comparative effectiveness of first-line (1L) cabozantinib (C) versus cabozantinib with nivolumab (C+N) in patients (pts) with metastatic papillary renal cell carcinoma (mPRCC).**  
First Author: Micah Ostrowski, MD
- Board B24 Abstract 462: Outcomes of delayed cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitor therapy.**  
First Author: Mohamed Soufi, MD
- Board B25 Abstract 463: Treatment patterns, attrition, and survival outcomes in patients with metastatic unclassified renal cell carcinoma.**  
First Author: Varun Nandakumar, MBBS
- Board B26 Abstract 464: Clinical efficacy of belzutifan in pre-treated renal cell carcinoma: A real world retrospective cohort benchmarked to LITESPARK-005.**  
First Author: Mousab Al Abbas
- Board C1 Abstract 465: Treatment (Rx) patterns and survival outcomes in patients with metastatic chromophobe renal cell carcinoma (mchRCC).**  
First Author: Richard Tanner Hardy, MD
- Board C2 Abstract 466: End-of-life treatment patterns in patients (pts) with metastatic renal cell carcinoma (mRCC).**  
First Author: Ayana Srivastava, BS
- Board C3 Abstract 467: Chromophobe renal cell carcinoma: Long-term survival and treatment patterns from a real-world cohort.**  
First Author: Leticia Kimie Murazawa, MD
- Board C4 Abstract 468: Perioperative outcomes of open versus robot-assisted radical nephrectomy with IVC thrombectomy.**  
First Author: Rishabh Simhal, MD
- Board C5 Abstract 469: Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database.**  
First Author: Rishabh Simhal, MD
- Board C6 Abstract 470: Optimal duration of immune checkpoint inhibitor therapy in genitourinary cancers: A systematic review and meta-analysis of real-world studies.**  
First Author: Insija Ilyas Selene, MD, MBBS
- Board C7 Abstract 471: Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma patients treated with adjuvant pembrolizumab at a tertiary care center.**  
First Author: Daniel Roadman, MD
- Board C8 Abstract 472: Clinical outcomes of retroperitoneal lymph node dissection in patients with cT<sub>3-4</sub> N<sub>x</sub> M<sub>0</sub> non-clear cell renal cell carcinoma.**  
First Author: Xianda Chen
- Board C9 Abstract 473: Adjuvant pembrolizumab in non-clear cell renal cell carcinoma after nephrectomy: An international multicenter study.**  
First Author: Razane El Hajj Chehade, MD
- Board C10 Abstract 474: Trends in overall survival with evolving systemic therapies for metastatic non-clear cell RCC: An analysis over two decades.**  
First Author: Mohammad Arfat Ganiyani, MBBS
- Board C11 Abstract 475: Real-world outcomes of clear-cell renal cell carcinoma (ccRCC) patients treated with belzutifan stratified by von Hippel-Lindau (VHL) status.**  
First Author: Parker Mathews, MD
- Board C12 Abstract 476: Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.**  
First Author: Michael R. Harrison, MD
- Board C13 Abstract 477: Real-world efficacy and safety of tivozanib in metastatic renal cell carcinoma in a diverse cohort: A multicenter study from the City of Hope enterprise.**  
First Author: Jadon Cooper Fann, BS
- Board C14 Abstract 478: Efficacy of subsequent therapy in patients with metastatic renal cell carcinoma of intermediate and poor risk following first-line immuno-oncology combinations.**  
First Author: Elena Tsareva
- Board C15 Abstract 479: Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).**  
First Author: Chris Labaki, MD
- Board C16 Abstract 480: Real-world effects of sodium-glucose cotransporter 2 inhibitor use on renal cell carcinoma.**  
First Author: Nikhila Sampath Kumar, MBBS
- Board C17 Abstract 481: Discrepancies in the administration of sequential therapies for metastatic renal cell carcinoma: Real-world practice versus randomized controlled trials.**  
First Author: Takuma Narita, MD

- Board C18 Abstract 482: Treatment utilization in metastatic renal cell carcinoma (mRCC) following implementation of a national cancer drug list (CDL) drug reimbursement program in Singapore: A real-world single-centre study.**  
First Author: Wei Chong Tan, MBBS
- Board C19 Abstract 483: Immune checkpoint inhibitor combinations in sarcomatoid metastatic clear cell renal cell carcinoma: A systematic review and meta-analysis.**  
First Author: Priya Kumar, MBBS
- Board C20 Abstract 484: Real world outcomes comparing the use of GLP-1 agonists in patients with renal cell carcinoma (RCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.**  
First Author: Yajur Arya, MD
- Board C21 Abstract 485: Bleeding risk with concurrent anticoagulation and VEGF-TKI therapy in mRCC: A real-world TriNetX analysis.**  
First Author: Love Kumar, MD
- Board C22 Abstract 486: Diabetic retinopathy as a marker for renal cell carcinoma among patients with type 2 diabetes mellitus.**  
First Author: Qinyun Cai
- Board C23 Abstract 487: Effect of remote exercise on fatigue and quality of life (QOL) across genitourinary (GU) cancer types.**  
First Author: Paulo Gustavo Bergerot, MD
- Board C24 Abstract 488: Incidence of symptomatic hypoxia in a high-altitude cohort of patients with renal cell carcinoma (RCC) treated with belzutifan.**  
First Author: Taylor R. McFarland, BS
- Board C25 Abstract 489: Guarding the kidneys in the immunotherapy era: Pooled incidence and severity of immune-related nephritis in renal-cell carcinoma treated with PD-1/PD-L1-based regimens.**  
First Author: Fnu Ashvin Rajeev Pillai, MD
- Board C26 Abstract 490: Emotional concerns due to kidney cancer (KC) and disparities in patient support across North America (NA): Results from the International Kidney Cancer Coalition (IKCC) global patient survey (GPS).**  
First Author: Eric Jonasch, MD
- Board D2 Abstract 492: A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma.**  
First Author: Jianbo Wang, MD, PhD
- Board D3 Abstract 493: Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2 $\alpha$  inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.**  
First Author: Toni K. Choueiri, MD, FASCO
- Board D4 Abstract 494: Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITSPARK-015 cohort B1.**  
First Author: Kan Gong, MD
- Board D5 Abstract 495: Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: An updated analysis with patient-derived organoid and immune co-culture insights.**  
First Author: Jun Du
- Board D6 Abstract 496: Response of venous tumor thrombi in renal cell carcinoma to immune checkpoint inhibitor therapy: A multicenter retrospective cohort study.**  
First Author: Eric Li, MD
- Board D7 Abstract 497: Fruquintinib combined with everolimus in Chinese patients with advanced/metastatic clear cell renal cell carcinoma (ccRCC) after progression on immune checkpoint inhibitors (ICIs): Results from a phase II single arm clinical trial.**  
First Author: Kaiwei Yang, MD
- Board D8 Abstract 498: Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.**  
First Author: Alexander Dean Sherry, MD
- Board D9 Abstract 499: Interim analysis of vorolanib combined with cadonilimab in previously untreated patients with advanced renal cell carcinoma.**  
First Author: Yabo Zhai, MD
- Board D10 Abstract 500: Pan-cancer assessment of deletions in COQ biosynthesis pathway genes associated with poor prognosis and potential benefit from BPM31510 intervention in kidney cancers.**  
First Author: Nischal Mahaveer Chand
- Board D11 Abstract 501: Cadonilimab plus lenvatinib in advanced renal cell carcinoma: Interim analysis of a prospective, multi-cohort phase II study.**  
First Author: Yabo Zhai, MD
- Board D13 Abstract 503: First results of a dose-escalation study evaluating *Clostridium butyricum* MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).**  
First Author: Miguel Zugman, MD
- Board D14 Abstract 504: Network meta-analysis of second- and later-line therapies in advanced renal cell carcinoma: A comparative effectiveness approach.**  
First Author: Isadora Mamede Mendes Da Silva, MD
- Board D15 Abstract 505: KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).**  
First Author: Laurence Albiges, MD, PhD
- Board D16 Abstract 506: A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non-clear cell renal cell carcinoma.**  
First Author: Xu Hu
- Board D17 Abstract 507: Long-term clinical outcomes with *Clostridium butyricum* MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).**  
First Author: Ali Moradi, MD

- Board D18** **Abstract 508: Characterization of depth and durability of response in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) who received cabozantinib plus nivolumab (C+N): Long-term follow-up and exploratory analysis of CheckMate 9ER.**  
First Author: Cristina Suárez, MD, PhD
- Board D19** **Abstract 509: Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma and venous tumor thrombus: Results from the first analysis of the PELET trial.**  
First Author: Mark Gluzman, MD
- Board D20** **Abstract 510: Pattern of disease recurrence and outcomes of localized high-risk renal cell carcinoma (RCC) patients treated with adjuvant (adj) immunotherapy: A single center experience.**  
First Author: Denis Occhipinti, MD
- Board D21** **Abstract 511: Long-term efficacy and patient experience with neoadjuvant cabozantinib for locally advanced renal cell carcinoma.**  
First Author: Mehmet Asim Bilen, MD
- Board D22** **Abstract 512: A novel cabozantinib formulation with reduced pharmacokinetic variability and the potential to improve safety in patients with renal cell carcinoma.**  
First Author: Jaymes S. Holland, BPharm
- Board D23** **Abstract 513: Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).**  
First Author: Karie Runcie, MD
- Board D24** **Abstract 514: *PARP1* and *BRCA1/2* expression and overall survival in high risk of recurrence localized clear cell-type renal cell carcinoma.**  
First Author: Donghyun Kim, MD, PhD
- Board D25** **Abstract 515: V-set immunoregulatory receptor as a novel molecular target for genitourinary cancers.**  
First Author: Kiyoshi Yanagisawa, MD
- Board D26** **Abstract 516: Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.**  
First Author: Paulo Siqueira do Amaral, MD
- Board E1** **Abstract 517: Use of spatial transcriptomics to analyze the molecular landscape of tuberous sclerosis complex-associated angiomyolipoma: Implications for diagnosis and therapeutic targeting.**  
First Author: Ryuta Watanabe, MD, PhD
- Board E2** **Abstract 518: Promoter methylation of aquaporin 1 as a prognostic biomarker in clear cell renal cell carcinoma.**  
First Author: Hirofumi Yoshino, MD
- Board E3** **Abstract 519: Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection.**  
First Author: Lin Lin, MD, PhD
- Board E4** **Abstract 520: Genome-wide association to identify SNPs associated with severe adverse events and clinical outcomes in advanced renal cell carcinoma treated with nivolumab.**  
First Author: Tokiyoshi Tanegashima
- Board E5** **Abstract 521: Association of prior 5- $\alpha$ -reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.**  
First Author: Bisheng Cheng
- Board E6** **Abstract 522: Association of enriched *YES1* tumor expression at the stromal interface with overall survival in clear cell renal cell carcinoma when treated with first-line immune checkpoint blockade.**  
First Author: Alyssa N. Obermayer, MSc
- Board E7** **Abstract 523: Use of genomic dedifferentiation signature to predict clinical outcomes with doublet vs triplet therapy in the phase III COSMIC-313 trial.**  
First Author: Nicholas Salgia, BSc
- Board E8** **Abstract 524: Integrative genomic landscape of germline exome alterations in renal cell carcinoma, unclassified with medullary phenotype.**  
First Author: Panayiotis D. Kontoyiannis, MD
- Board E9** **Abstract 525: Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.**  
First Author: Paulo Siqueira do Amaral, MD
- Board E10** **Abstract 526: Unveiling sex-based disparities in advanced renal cell carcinoma: Insights from the real-world Meet-URO33 (REGAL) study.**  
First Author: Eleonora Lai, MD
- Board E11** **Abstract 527: Peripheral blood correlates of outcomes with adjuvant tremelimumab plus durvalumab for patients with renal cell carcinoma at high or intermediate risk of relapse: Initial results from the TransRAMPART study.**  
First Author: James Owain Jones, PhD, MBBCh, MRCP
- Board E12** **Abstract 528: Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients.**  
First Author: Yu-Wei Chen, MD, MS
- Board E13** **Abstract 529: *MTAP* loss in sarcomatoid renal cell carcinoma (srcRCC): A genomic landscape study.**  
First Author: Michael A. Daneshvar, MD, MS
- Board E14** **Abstract 530: Metabolic reprogramming in chromophobe renal cell carcinoma: Transcriptomic insights into the transition from indolent to aggressive disease.**  
First Author: Mohammed Osama Ahamd Bader, MBBS
- Board E15** **Abstract 531: Correlation without causality between *BAP1* loss and the metastasis-associated *miR-183/96/182* cluster expression in renal cell carcinoma.**  
First Author: Julian Heidenreich, MD

- Board E16 Abstract 532: Association of pre-operative circulating tumor DNA (ctDNA) status with clinicopathologic characteristics in patients (pts) with localized renal cell carcinoma (RCC).**  
First Author: Shuchi Gulati, MD, FACP, MS
- Board E17 Abstract 533: VHL wild-type clinically advanced clear cell renal cell carcinoma (ccRCC): A genomic landscape study.**  
First Author: Rebecca A. Sager, MD, PhD
- Board E18 Abstract 534: Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma.**  
First Author: Akihiro Kumono
- Board E19 Abstract 535: Molecular and clinical correlates of early-onset clear cell renal cell carcinoma (ccRCC): A real-world multi-omics analysis.**  
First Author: Hedyeh Ebrahimi, MD, MPH
- Board E20 Abstract 536: Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma.**  
First Author: Hanae Kondo Sr
- Board E22 Abstract 538: Circulating kidney injury marker-1 (KIM-1) in metastatic renal cell carcinoma with divergent histologies (RCCdh): Biomarker analysis of the CAN-I trial.**  
First Author: Wenxin Xu, MD
- Board E23 Abstract 539: Kidney injury molecule-1 (KIM-1) in localized and metastatic renal cell carcinoma (RCC): A meta-analysis and systematic review.**  
First Author: Mattia Alberto Di Civita
- Board E24 Abstract 540: Pilot phase I trial of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma.**  
First Author: Clara Steiner, MD
- Board E25 Abstract 541: Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.**  
First Author: David F. McDermott, MD
- Board E26 Abstract 542: Effect of tryptophan-serotonin-kynurenine pathways on immune landscape and survival in clear cell renal cell carcinoma: TCGA-KIRC transcriptomic analysis.**  
First Author: Ecem Kalemoglu, MD, PhD
- Board F1 Abstract 543: Germline platelet polygenic risk score to predict renal cell carcinoma survival via sustained thrombocytosis.**  
First Author: Mustafa Saleh, MD
- Board F2 Abstract 544: Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101.**  
First Author: Steven Monda, MD, MSCI
- Board F3 Abstract 545: Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).**  
First Author: Neeraj Agarwal, MD, FASCO
- Board F4 Abstract 546: Development and validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in renal cell carcinoma.**  
First Author: Alex Zhu, DO
- Board F5 Abstract 547: Analysis of CA9 and PSMA expression in clear cell renal cell carcinoma (ccRCC) and the effect of prior therapies.**  
First Author: Gabriel Roberti De Oliveira, MD
- Board F6 Abstract 548: Expansion and characterization of tumor-infiltrating lymphocytes from primary and metastatic immune checkpoint inhibitor-exposed renal cell carcinoma tumors.**  
First Author: Marine Potez
- Board F7 Abstract 549: Pathologic response after neoadjuvant therapy in renal cell carcinoma using irRVT criteria.**  
First Author: Benjamin J. Croll, MD
- Board F8 Abstract 550: Circulating angiogenic-myeloid cytokine axis to predict benefit from first-line immune-checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.**  
First Author: Mariangela Calabrese, MD
- Board F9 Abstract 551: Succinate dehydrogenase B deficient renal cell carcinoma (RCC): A genomic landscape study.**  
First Author: Sibtain Mustafa, MD
- Board F10 Abstract 552: Single-cell transcriptomic investigation of the cell-of-origin and oncogenic pathways across variant histologies of renal cell carcinoma.**  
First Author: Zachary Alan Yochum, MD, PhD
- Board F11 Abstract 553: Baseline and longitudinal body composition profile association with immune-checkpoint inhibitor (ICI) outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).**  
First Author: Ardit Feinaj, MD
- Board F12 Abstract 554: Association of SETD2 mutation with prognostic features and susceptibility to acute kidney injury in renal cell carcinoma.**  
First Author: Vida Tajiknia
- Board F13 Abstract 555: Correlation of mutated *B2M*, an immune-related gene, with overall survival in renal cell carcinoma.**  
First Author: Lauren Luu
- Board F14 Abstract 556: Prevalence and clinical impact of actionable genomic alterations in non-clear cell renal cell carcinoma: A review of NGS-based trials and real-world data.**  
First Author: Bruno R. Bastos, MD
- Board F15 Abstract 557: KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.**  
First Author: Sara Coca Membrives
- Board F16 Abstract 558: Predictors and clinical outcomes of renal tumor upstaging from cT1 to pT3a disease in patients who underwent robot-assisted partial nephrectomy.**  
First Author: Abdulrahman Al-Bayati, MD

- Board F17** **Abstract 559: Healthy donor fecal microbiota transplantation combined with immunotherapy in metastatic renal cell carcinoma: Results from the phase I PERFORM trial.**  
First Author: Ricardo Fernandes, MD
- Board F18** **Abstract 560: Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.**  
First Author: Balaji Venugopal, MD, MBBS, FRCP
- Board F19** **Abstract 561: Evaluating the relationship between vasculitis and metastasis in kidney-related urogenital cancers: A multicenter real-world propensity-matched cohort study.**  
First Author: Pallab Sarker, MBBS
- Board F20** **Abstract 562: Early monitoring of derived neutrophil-to-lymphocyte ratio (dNLR) as a predictive biomarker of benefit to immune checkpoint inhibitors (ICI) in advanced clear cell renal cell carcinoma (ccRCC).**  
First Author: Marina Sierra, MD
- Board G1** **Abstract 563: Prognostic value of baseline serum IgG in metastatic clear cell renal cell carcinoma treated with first-line IO–TKI therapy.**  
First Author: Hongwei Wang, MD
- Board G2** **Abstract 564: Clinical significance of baseline serum IgG in metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy.**  
First Author: Hongwei Wang, MD
- Board G3** **Abstract 565: Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.**  
First Author: Mohammad Jahanzeb, MD, FACP, FASCO
- Board G4** **Abstract 566: Clinical characteristics and survival outcomes of primary sarcoma of the kidney (PSK).**  
First Author: Hyun Lee, MD
- Board G5** **Abstract 567: Leveraging large language models (LLM) to guide adjuvant treatment recommendations for renal cell carcinoma (RCC) after nephrectomy.**  
First Author: Fouad Nahhat, MD
- Board G6** **Abstract 568: Incidence of adolescent and young adult renal cell carcinoma in the modern era.**  
First Author: Vivian Wong, MD
- Board G7** **Abstract 588: Impact of serum LDH on clinical outcomes in patients with good-risk metastatic non-seminomatous germ cell-cell tumors (NSGCT).**  
First Author: Ahmed Bilal Khalid, MBBS
- Board G8** **Abstract 589: Performance of circulating tumor DNA as a biomarker in testicular seminoma and non-seminomatous germ cell tumor patients undergoing primary retroperitoneal lymph node dissection.**  
First Author: Parth Thakker, MD, MS
- Board G9** **Abstract 590: Circulating tumor DNA performance in primary retroperitoneal lymph node dissection: A stage-based analysis.**  
First Author: Parth Thakker, MD, MS
- Board G10** **Abstract 591: Prognostic factors affecting racial impact in testicular cancer outcomes in the United States.**  
First Author: Eun-mi Yu, MD
- Board G11** **Abstract 592: Bridging global gaps: Expanding GU oncology education through iECHO telementoring.**  
First Author: Martin Angel, MD
- Board G12** **Abstract 593: Contemporary survival and treatment outcomes in malignant spermatic-cord tumors: A two-decade population-based analysis.**  
First Author: Aqsa Zoey Sorathia, MD
- Board G13** **Abstract 594: Demographic predictors of primary retroperitoneal lymph node dissection (P-RPLND) vs. primary chemotherapy (P-Ch) in the treatment of clinical stage IIA/B (CSIIA/B) non-seminomatous testicular germ cell tumors (NSGCTs).**  
First Author: J. Everett Knudsen
- Board G14** **Abstract 595: Ethnic disparities and variations in testicular germ cell tumours: A retrospective real-world analysis in a single tertiary cancer centre.**  
First Author: Suha Abdulla, MRCP, MS, MBBS
- Board G15** **Abstract 596: Second opinions and treatment guidance in non- or minimally metastatic testicular cancer: Is ChatGPT 5 non-inferior to expert recommendations?**  
First Author: Tim Nestler, MD
- Board G16** **Abstract 597: Conventional-dose chemotherapy as first salvage in germ cell tumors: Outcomes from an Ibero-American multi-institutional cohort.**  
First Author: Iván Macharashvili, MD
- Board G17** **Abstract 598: Benign persistent elevation of alphafoetoprotein (AFP) after curative treatment for germ-cell tumors.**  
First Author: Solenn Barraud, MD
- Board G18** **Abstract 599: Surveillance after complete response (CR) to first-line chemotherapy (chemo) in non-seminomatous germ-cell tumor (NSGCT).**  
First Author: Towfik Sebai, MD
- Board G19** **Abstract 600: Impact of bleomycin shortage on real-world outcomes in germ cell tumors: A multicenter retrospective analysis in Brazil.**  
First Author: Jean Marcelo Strippoli Doffini, MD
- Board G20** **Abstract 601: Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.**  
First Author: Henry Yen-Cheng Pan, MBBS, BMedSci
- Board H1** **Abstract 602: Turning the tide in recurrent NSGCT: Retrospective insights into TIP vs non-TIP salvage chemotherapy.**  
First Author: Amrit Dhar, MD

- Board H2 Abstract 603: Contemporary patterns of treatment and outcomes in germ-cell tumors across a provincial cancer system: British Columbia Germ Cell Tumor Clinical Database.**  
First Author: Mateus Zapparoli Claro, MD
- Board H3 Abstract 604: Prognostic utility of lactate dehydrogenase in patients with metastatic seminoma.**  
First Author: Mert Sevgi, MD
- Board H4 Abstract 605: Survivorship outcomes of stage I testis cancer management.**  
First Author: Adri Durant, MD
- Board H5 Abstract 606: Serum amyloid A4 and cognitive functioning in long-term testicular germ cell tumor survivors.**  
First Author: Zuzana Orszaghova, MD
- Board H6 Abstract 607: Subclinical hepatic injury and risk of nonalcoholic steatohepatitis after adjuvant systemic therapy in early-stage testicular cancer survivors.**  
First Author: Julio Cesar Cesar Ulloa Garcia, MD
- Board H7 Abstract 608: Surveillance of patients with complete response following first-line chemotherapy for germ cell tumors: Focus on lifestyle, socioeconomic, and sexual health outcomes.**  
First Author: Phichai Chansriwong, MD
- Board H8 Abstract 609: Oncological outcomes of primary retroperitoneal lymph node dissection in patients with clinical stage IIB seminoma: A binational retrospective analysis.**  
First Author: Julian Heidenreich, MD
- Board H9 Abstract 610: Vertebral surgery in the management of complex postchemotherapeutic retroperitoneal lymph node dissection (PC-RPLND).**  
First Author: Axel Heidenreich, MD
- Board H10 Abstract 611: Post-chemotherapy retroperitoneal lymph node dissection for patients with metastatic pure seminoma.**  
First Author: Viranda Jayalath, MD, MSc
- Board H11 Abstract 612: Impact of bleomycin dose omissions on clinical outcomes in non-seminomatous germ cell tumors: A systematic review and meta-analysis.**  
First Author: Muhammad Shaheer Mannan, MD
- Board H12 Abstract 613: Divergent biology and outcomes of somatic transformations (SM) in germ cell tumors (GCT).**  
First Author: Zachariah Thomas, MBBS
- Board H13 Abstract 614: Parallel liquid biopsy analysis of miR-371a-3p and cell-free DNA in testicular germ cell tumors.**  
First Author: Laura Matouskova
- Board H14 Abstract 615: Progression after first-line chemotherapy with normal serum tumor markers (STM) in non-seminomatous germ-cell tumors (NSGCT).**  
First Author: Towfik Sebai, MD
- Board H15 Abstract 616: miR-371a-3p as a potential biomarker for monitoring disease activity and therapeutic response in metastatic seminoma and non-seminomatous germ cell tumor patients treated with BEP chemotherapy.**  
First Author: Olivia Steenbock, MD
- Board H16 Abstract 617: Genomic analyses of bilateral testicular germ cell cancers (BITCOIN study) from the Italian Germ Cell Cancer Group (IGG).**  
First Author: Sara Erika Bellomo
- Board H17 Abstract 618: Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.**  
First Author: Valentina Tateo, MD
- Board H18 Abstract 619: Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT): A proof-of-concept study.**  
First Author: Zachariah Thomas, MBBS
- Board H19 Abstract 620: Use of circulating tumor DNA (ctDNA) in the detection of residual disease and recurrence for patients with testicular cancer.**  
First Author: Dalia Kaakour, MD, MS, MPH
- Board H20 Abstract 621: Cross institutional comparison of the miR-371a-3p assay in pre-surgical germ cell tumor (GCT) patients.**  
First Author: Adam Levin
- Board H21 Abstract 622: SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.**  
First Author: Antoine Morin Coulombe, MD, FRCPC
- Board H22 Abstract 627: Primary urethral squamous cell carcinoma: Insights and outcomes from a 27-year institutional experience.**  
First Author: Mazyar Zahir, MD

7:00 AM-8:10 AM and 11:30 AM-12:45 PM  
**Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular, and Urethral Cancers**  
 Level 1, West Hall

**Posters by Topic**

**Adrenal Cancer**

- Therapeutics: H23

**Renal Cell Cancer**

- Diagnostics and Imaging: H24
- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: H25
- Therapeutics: H26, J1-J13
- Other: J22

**Testicular Cancer**

- Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care: J23
- Therapeutics: J24-J26

- Board H23** **Abstract TPS2: Obixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.**  
 First Author: Marianne Pavel, MD
- Board H24** **Abstract TPS569: A phase 1/2 study to assess peptidomimetic carbonic anhydrase IX imaging and therapy with [<sup>68</sup>Ga]Ga-DPI-4452 and [<sup>177</sup>Lu]Lu-DPI-4452 in patients with advanced clear cell renal cell carcinoma and other solid tumors.**  
 First Author: Michael S. Hofman, MBBS, FRACP
- Board H25** **Abstract TPS570: Digital monitoring of self-reported symptoms by patients treated with cabozantinib plus nivolumab for advanced clear-cell renal carcinoma (CANIQOL).**  
 First Author: Romain Levard, MD, MSc, PharmD
- Board H26** **Abstract TPS571: TANKeR-70: TGF-β-receptor type 2 knockout allogeneic NK cells for renal cell carcinoma expressing CD70.**  
 First Author: Andrew Johns, MD
- Board J1** **Abstract TPS572: ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.**  
 First Author: Sarah Elizabeth Yentz, MD
- Board J2** **Abstract TPS573: Ivonescimab in metastatic clear cell renal cell carcinoma (mccRCC) after immune checkpoint inhibitor therapy: The phase II IVORY trial.**  
 First Author: Nazli Dizman, MD
- Board J3** **Abstract TPS574: REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.**  
 First Author: Laurence Albiges, MD, PhD
- Board J4** **Abstract TPS575: A multicenter, open-label, phase II study of adaptive combination immunotherapy with VEGFR-TKI for advanced renal cell carcinoma.**  
 First Author: Justin Miller, BSc

- Board J5** **Abstract TPS576: Systemic therapy combined with radiotherapy versus systemic therapy alone for oligometastatic kidney cancer (STROKER): A multicenter, randomized controlled phase III trial.**  
 First Author: Qiwen Pan
- Board J6** **Abstract TPS577: Short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma: STRIKE! (Alliance A032201).**  
 First Author: Bradley Alexander McGregor, MD, FASCO
- Board J7** **Abstract TPS578: Phase 1/2 dose escalation/ expansion study of REGN10597 (anti-PD-1-IL2Rα-IL2) in patients with advanced solid tumors.**  
 First Author: Kyriakos Papadopoulos
- Board J8** **Abstract TPS579: Phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan plus zanzalitinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma during or after anti-PD-(L)1 therapy.**  
 First Author: Robert J. Motzer, MD
- Board J9** **Abstract TPS580: A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.**  
 First Author: Eric Jonasch, MD
- Board J10** **Abstract TPS581: A phase II study bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC).**  
 First Author: Tian Zhang, MD, MHS, FASCO
- Board J11** **Abstract TPS582: Phase 1B/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment-naïve patients with advanced clear cell RCC.**  
 First Author: Eric Jonasch, MD
- Board J12** **Abstract TPS583: A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).**  
 First Author: Ilya Tsimafeyeu, MD
- Board J13** **Abstract TPS584: The ITALIC-RCC study: A randomized study of clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy.**  
 First Author: Paola Troisi
- Board J22** **Abstract TPS585: Phase 1/2 OMAHA-U01 substudy 01A: Oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).**  
 First Author: Arif Hussain, MD, PhD
- Board J23** **Abstract TPS623: P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**  
 First Author: Blossom Mak, PhD, MBBS

**Board J24 Abstract TPS624: ASPIRE GCT: A single-arm, phase II clinical trial of aspirin to prevent venous thromboembolism in patients with advanced germ cell tumors receiving chemotherapy.**  
First Author: Landon Carter Brown, MD

**Board J25 Abstract TPS625: Randomized phase II trial of maintenance oral etoposide versus observation following high-dose chemotherapy and peripheral blood stem cell transplant in relapsed non-seminomatous germ cell tumors.**  
First Author: Towfik Sebai, MD

**Board J26 Abstract TPS626: Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT).**  
First Author: Ahmed Bilal Khalid, MBBS

## Industry Expert Theater

Industry Expert Theater (IET) sessions, located in the West Hall on Level 1, bring together industry leaders and attendees for 45-minute, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies. If the IET company chooses to post their in-person session recording online, the session audio and slides will be available at [asco.org/gu-program](https://asco.org/gu-program) for on-demand viewing, within 1 week of the conclusion of the Symposium.

IET sessions are not official presentations of the 2026 ASCO Genitourinary Cancers Symposium and are not sponsored, endorsed, or accredited by ASCO, or Conquer Cancer, the ASCO Foundation. These sessions are not CME accredited.

Schedule is current as of January 9, 2026. For the most up-to-date information, visit [gu.asco.org](https://gu.asco.org)

### Thursday, February 26

**Time:** 11:45 AM–12:30 PM

**Title:** A New PARPi Indication for Your Patients with BRCA-Mutated mCRPC

**Description:** Learn about the expanded indication for RUCAPARIB® (rucaparib) for patients with BRCA-mutated mCRPC. This session will review treatment options, the TRITON3 clinical data, and patient considerations to optimize care in this evolving landscape, especially for patients looking to avoid chemotherapy.

**Company:** Tolmar Inc.

**Presenter:** Kanwarjit Singh, M.D., Vice President of Medical Affairs, Tolmar Inc.

---

**Time:** 6:00 PM–6:45 PM

**Title:** Evolution of Real-World Evidence

**Description:** This program will cover: An overview of the evolution of RWE and the rigor needed to enhance treatment effectiveness and patient outcomes.

**Company:** Johnson & Johnson

**Presenters:**

Mukul Singhal, PhD, Director, Real World Value & Evidence, Johnson & Johnson  
Sirach Selassie, MD, Medical Director, US Medical Affairs, Johnson & Johnson

### Friday, February 27

**Time:** 10:15 AM–11:00 AM

**Title:** Clinical Insights in the Treatment of Advanced Prostate Cancer: Androgen Deprivation Therapy and Cardiovascular Risk

**Description:** Studies suggest that androgen deprivation therapies may carry varying cardiovascular (CV) risk. This symposium will review CV disease in prostate cancer and evidence from a recent clinical trial assessing coronary atherosclerosis in men receiving the GnRH antagonist relugolix vs a GnRH agonist.

**Company:** Sumitomo Pharma America, Inc.

**Presenter:** Jatin Shah, MD, Chief Medical Officer – Oncology, Sumitomo Pharma America, Inc.

---

**Time:** 11:45 AM–12:30 PM

**Title:** The Role of PTEN in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

**Description:** PTEN Deficiency in mHSPC: the unmet need, prognostic significance, and biomarker testing.

**Company:** AstraZeneca

**Presenter:** Zhengtao Qin, MD, AstraZeneca

---

**Time:** 5:00 PM–5:45 PM

**Title:** A Review of Clinical Decision Making in HER2+ Metastatic Solid Tumors After Prior Systemic Treatment

**Description:** This program will cover: Approaches for detecting HER2+(IHC 3+) in metastatic bladder cancer, efficacy and safety data for ENHERTU in patients with previously treated HER2+(IHC 3+) metastatic solid tumors, and guidelines for HER2-directed therapy for HER2+ (IHC 3+) metastatic bladder cancer.

**Company:** AstraZeneca and Daiichi Sankyo, Inc.

**Presenter:** Stephen Hull, MD, MBA, Medical Director, AstraZeneca

# Exhibitor Directory

## Level 1, West Hall

The exhibits are open on Thursday, February 26 from 7:00 AM to 6:45 PM and Friday, February 27 from 7:00 AM to 5:45 PM in the West Hall on Level 1.

The most up-to-date list of exhibitors and a floorplan highlighting the location of each exhibitor can be found online at [gu.asco.org](http://gu.asco.org).

The Exhibitor Directory provides oncologists and other health care professionals with information about companies and their products and services. The Exhibitor Directory does not represent endorsement by American Society of Clinical Oncology ("ASCO"), either express or implied, of any exhibitor, product, or service. ASCO does not make any warranty concerning the accuracy or reliability of any information contained in this directory and ASCO disclaims any and all responsibility for and liability relating to all such information. The use of the name, logo, or marks of ASCO is strictly prohibited without the prior written consent of ASCO. The information contained in this directory may not be used in any way with or without reference to ASCO's name, logo, or marks without the prior written consent of ASCO.

If an exhibitor scans your badge, you are sharing your contact data with the exhibitor, and you consent to be contacted by the exhibitor. If you have questions about how an exhibitor uses data, please contact the exhibitor or see their privacy policy.

© denotes Conquer Cancer, the ASCO Foundation Donor and/or Conquer Cancer Council Member as of January 7, 2026.

*\*Information listed below is current as of January 9, 2026.*

### AbbVie ©

[abbvie.com](http://abbvie.com)

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit our website. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

### American Society for Radiation Oncology (ASTRO)

[astro.org](http://astro.org)

The American Society for Radiation Oncology (ASTRO) is the leading society for radiation oncology. We're dedicated to improving patient care through education and training, support for clinical practice and health policy standards, advancement of science and research and advocacy. Stop by our booth to learn about membership, upcoming meetings, patient education materials specific to GU, APEX - ASTRO's Accreditation Program for Excellence and RO-ILS: Radiation Oncology Incident Learning System.

### Amgen Inc. ©

[amgen.com](http://amgen.com)

### Artera

[artera.ai](http://artera.ai)

### ASCO®

[asco.org](http://asco.org)

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary oncology organizations representing more than 50,000 oncology professionals across every cancer specialty. Through research, education, and promotion of the highest quality, equitable patient care, our members work to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

### ASCO® Digital Initiatives

[asco.org](http://asco.org)

Help improve ASCO's apps and websites by taking a 5-minute survey onsite in the West Hall on Level 1. Share your feedback and receive an ASCO drink tumbler (while supplies last).

### Astellas Pharma ©

[stellasoncology.com](http://stellasoncology.com)

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website.

### AstraZeneca ©

[astrazeneca-us.com](http://astrazeneca-us.com)

### AVEO Oncology, an LG Chem company

[aveooncology.com](http://aveooncology.com)

AVEO Oncology ("AVEO") is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients' lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. ("LG Chem"), establishing a U.S. commercial presence for LG Chem and expanding LG Chem's global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit [FOTIVDAHCP.com](http://FOTIVDAHCP.com).

### Bayer ©

[pharma.bayer.com](http://pharma.bayer.com)

### BillionToOne

[billiontoone.com](http://billiontoone.com)

### BioNTech ©

[biontech.com](http://biontech.com)

BioNTech is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies.

### Blue Earth Diagnostics, Inc.

[blueearthdiagnostics.com](http://blueearthdiagnostics.com)

### Boehringer Ingelheim Pharmaceuticals, Inc.

[boehringer-ingelheim.com](http://boehringer-ingelheim.com)

### Bristol Myers Squibb ©

[bms.com](http://bms.com)

**Canadian Urological Association**

cua.org

**Caris Life Sciences**

carislifesciences.com

**Cencora**

cencora.com

**City of Hope**

cityofhope.org

**Clarity Pharmaceuticals**

claritypharmaceuticals.com

**Curium**

curiumpharma.com

**Daichi Sankyo**

dsj.com

**DAVA Oncology**

davaonc.com

**Decipher Urologic Cancers, Subsidiary of Veracyte**

veracyte.com/decipher

**Dendreon Pharmaceuticals, LLC**

dendreon.com

**Eisai Inc.**

eisai.com/us

**Eisai Inc. Medical Information**

eisai.com/us

**Eli Lilly and Company**

lilly.com

**EMD Serono**

emdserono.com/us-en

**enGene**

engene.com

**Exelixis**

exelixis.com

**Exelixis Medical Affairs**

exelixismedicalaffairs.com

**Fennec Pharmaceuticals**

fennecpharma.com

**Ferring Pharmaceuticals**

ferring.com

**Ferring Pharmaceuticals Inc.**

ferringurooncology.com

**Flatiron Health**

flatiron.com

**Foundation Medicine**

foundationmedicine.com

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.

**Genentech**

gene.com

**GSK Medical Oncology**

gskusmedicalaffairs.com/oncology

**Imaging Endpoints**

imagingendpoints.com

**ImmunityBio, Inc.**

immunitybio.com

**Johnson & Johnson**

jnj.com

**Kidney Cancer Association**

kidneycancer.org

**Lantheus**

lantheus.com

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit our website.

**Merck & Co., Inc.**

merck.com

**MERIT**

meritcro.com

**Myriad Genetics**

myriad.com/oncology

**Natera, Inc.**

natera.com/oncology

Signatera™ is a personalized, tumor-informed assay, optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Results are based on the unique signature of a patient's tumor by tracking mutations at the source and enabling accurate monitoring of disease over time. Discover more on our website.

**Novartis Pharmaceuticals Corporation**

novartis.com

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

**Pfizer Oncology** 

[pfizeroncologycongressresources.com/obu/r](http://pfizeroncologycongressresources.com/obu/r)

Our vision is a world where people with cancer live better and longer lives. We are accelerating breakthrough cancer medicines that bring new hope to patients everywhere. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies, including other immune-oncology biologics.

**Predicine Inc.**

[predicine.com](http://predicine.com)

Predicine is a global molecular insights company committed to advancing precision medicine through innovative liquid biopsy and tissue-based genomic testing solutions. With a robust portfolio of proprietary assays, Predicine enables biopharma partners, clinical researchers, and healthcare providers to accelerate drug development and optimize treatment strategies for patients worldwide.

**Protara Therapeutics**

[protaratx.com](http://protaratx.com)

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin. For more information, visit our website.

**Rocky Mountain Poison and Drug Safety**

[rmpds.org](http://rmpds.org)

**Sumitomo Pharma America, Inc. (Medical)** 

[us.sumitomo-pharma.com](http://us.sumitomo-pharma.com)

**Sumitomo Pharma America/Pfizer** 

[us.sumitomo-pharma.com](http://us.sumitomo-pharma.com)

**Syncromune, Inc.**

[syncromune.com](http://syncromune.com)

**Telix Pharmaceuticals (US) Inc.**

[telixpharma.com](http://telixpharma.com)

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic ('theranostic') products using targeted radiation. Our products use targeted radiation to image disease and deliver truly personalized therapy in areas of significant unmet medical need. Telix's theranostic pipeline aims to address significant unmet medical need in prostate, kidney, brain, and blood cancers, and a range of rare diseases.

**Tempus**

[tempus.com](http://tempus.com)

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare.

**The ASCO Post**

[ascopost.com](http://ascopost.com)

**Tolmar Inc.**

[tolmar.com](http://tolmar.com)

**Tyra Biosciences, Inc.**

[tyra.bio](http://tyra.bio)

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÁP, enables rapid and precise drug design through iterative molecular SNÁPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions.

**UroGen Pharma Inc.**

[urogen.com](http://urogen.com)

**Vaniam Group**

[vaniamgroup.com](http://vaniamgroup.com)